[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 202
1. Zhang J, Jianmin, Wang N, Shi J, Ge X: A case of primary oncocytic adenocarcinoma of the lacrimal sac. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary oncocytic adenocarcinoma of the lacrimal sac.
  • Neoplasms of the lacrimal system may conveniently be grouped into epithelial and non-epithelial types: papillomas are the most common benign epithelial tumours, while oncocytic adenocarcinomas are extremely rare.
  • Here we report a case of primary oncocytic adenocarcinoma of the lacrimal sac in a 56-year-old man.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orbit. 2005 Dec;24(4):291-3 [16354642.001]
  • [Cites] Ophthalmology. 1980 Jun;87(6):476-90 [7413136.001]
  • [Cites] Ear Nose Throat J. 1995 Oct;74(10):717-20 [8529551.001]
  • [Cites] Ophthalmic Surg. 1995 Jul-Aug;26(4):377-9 [8532297.001]
  • [Cites] Arch Ophthalmol. 1978 Feb;96(2):303-4 [629677.001]
  • (PMID = 21747898.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029480
  •  go-up   go-down


2. Al-Abed Y, Gray E, Wolfe K, Watters GW, Philpott JM: Metastatic Hurthle Cell Carcinoma of the thyroid presenting as a Breast Lump: A Case Report. Int Semin Surg Oncol; 2008;5:14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle Cell Carcinoma of the thyroid presenting as a Breast Lump: A Case Report.
  • BACKGROUND: Hurthle cell carcinoma of the thyroid is a rare form of thyroid cancer.
  • It may present as a low grade tumour or can present as a more aggressive metastatic carcinoma.
  • Hurthle cell carcinoma has the highest incidence of metastasis among all differentiated thyroid cancers.
  • We present the first case of breast metastasis from Hurthle cell carcinoma of the thyroid.
  • CASE PRESENTATION: We report a 77 year old lady who had total thyroidectomy and bilateral neck dissection followed by radiotherapy for a high grade metastatic Hurthle cell carcinoma of the thyroid.
  • Fine needle aspiration cytology of the lumps and histology after wide local excision of the breast lump confirmed metastatic Hurthle cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1991 Oct;48(2):112-6 [1921396.001]
  • [Cites] Int J Surg. 2006;4(4):204-5 [17462351.001]
  • [Cites] J Postgrad Med. 2005 Apr-Jun;51(2):125-7 [16006706.001]
  • [Cites] Onkologie. 2004 Oct;27(5):469-71 [15585977.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1293-300 [8960043.001]
  • [Cites] Breast. 2004 Apr;13(2):155-8 [15019699.001]
  • [Cites] Radiology. 1982 Jul;144(2):309-12 [7089284.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] World J Surg Oncol. 2004;2:27 [15306032.001]
  • (PMID = 18505578.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409361
  •  go-up   go-down


3. Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B: Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases. Cancer; 2006 Apr 15;106(8):1669-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
  • BACKGROUND: Follicular carcinomas of the thyroid gland, including its oncocytic variant (so-called Hurthle cell carcinoma), are subdivided into the indolent encapsulated ("minimally invasive") and the clinically aggressive widely invasive tumors.
  • There are, however, cases of encapsulated follicular carcinoma that recur and metastasize.
  • Identifying these cases at the time of diagnosis is crucial for prognostic and therapeutic considerations.
  • Because to the authors' knowledge most studies do not focus exclusively on the encapsulated Hurthle cell carcinoma (EHC), the current study attempted to identify predictors of recurrence in EHC.
  • METHODS: A tumor was defined as EHC if it was encapsulated, macroscopically well defined with microscopic but no macroscopic evidence of vascular or capsular invasion, and composed of > 75% follicular oncocytic cells.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / secondary. Neoplasm Recurrence, Local. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16534796.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Pusiol T, Franceschetti I, Piscioli I, Beltrame MA, Polce M, Sassi C: Value of imaging and aspiration cytology in the diagnosis of oncocytic carcinoma. Acta Otorhinolaryngol Ital; 2010 Apr;30(2):110-4
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of imaging and aspiration cytology in the diagnosis of oncocytic carcinoma.
  • Oncocytic carcinoma of the parotid gland is a rare neoplasm.
  • To the best of our knowledge the simultaneous occurrence of oncocytic carcinoma and second malignancy in another site (outside the parotid gland) has not been reported.
  • An oncocytic carcinoma of the parotid gland is described in 56-year-old male with simultaneous breast cancer, emphasising the value of aspiration cytology and imaging procedures in the diagnosis of parotideal neoplasms.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiography. Carcinoma / pathology. Carcinoma / radiography. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography. Parotid Neoplasms / pathology. Parotid Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1989-92 [11801984.001]
  • [Cites] Acta Otolaryngol. 2008 Oct;128(10):1152-8 [18607904.001]
  • [Cites] Ear Nose Throat J. 2003 Sep;82(9):699-701 [14569705.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1099-102 [14674089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Laryngol Otol. 1965 Dec;79(12):1064-72 [5858167.001]
  • [Cites] Br J Surg. 1971 Nov;58(11):851-3 [5124858.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):351-6 [3473871.001]
  • [Cites] Radiology. 1987 Oct;165(1):183-9 [3628768.001]
  • [Cites] Diagn Cytopathol. 1991;7(4):420-2 [1935522.001]
  • [Cites] Otolaryngol Head Neck Surg. 1991 Dec;105(6):868-76 [1787978.001]
  • [Cites] Ann Pathol. 1991;11(5-6):359-62 [1804158.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):479-82 [1571115.001]
  • [Cites] Indian J Cancer. 1992 Dec;29(4):230-3 [1293011.001]
  • [Cites] Cytopathology. 1994 Apr;5(2):110-3 [8038421.001]
  • [Cites] Diagn Cytopathol. 1994 Dec;11(4):376-9 [7895576.001]
  • [Cites] Cytopathology. 1995 Feb;6(1):54-8 [7734704.001]
  • [Cites] Am J Otolaryngol. 1995 May-Jun;16(3):200-4 [7661319.001]
  • [Cites] Cancer. 1998 Jun 25;84(3):153-9 [9678729.001]
  • [Cites] J Oral Maxillofac Surg. 1999 Mar;57(3):325-8 [10077205.001]
  • [Cites] AMA Arch Pathol. 1953 Apr;55(4):328-46 [13030050.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6 [15668471.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):567-9 [15592856.001]
  • [Cites] J Otolaryngol. 2006 Jun;35(3):189-92 [16929996.001]
  • [Cites] Onkologie. 2006 Sep;29(8-9):388-90 [16974117.001]
  • [Cites] Br J Plast Surg. 2003 Oct;56(7):637-43 [12969661.001]
  • (PMID = 20559483.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2882149
  • [Keywords] NOTNLM ; Fine-needle aspiration cytology / Male breast cancer / Malignant tumours / Oncocytic carcinoma / Parotid gland
  •  go-up   go-down


5. McHugh JB, Hoschar AP, Dvorakova M, Parwani AV, Barnes EL, Seethala RR: p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma. Head Neck Pathol; 2007 Dec;1(2):123-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma.
  • Metastatic renal cell carcinoma (RCC) can pose diagnostic challenges in the head and neck often resembling benign and malignant oncocytic lesions.
  • Nineteen oncocytomas, 9 cases of oncocytosis, 9 oncocytic carcinomas and 16 head and neck metastatic RCC were studied.
  • Morphologic features evaluated were cytoplasmic character (clear versus oncocytic), Fuhrman nuclear grade, mitotic rate, growth pattern, presence of lumens/blood lakes and stromal characteristics.
  • Tumors were stained with antibodies to p63, renal cell carcinoma marker (RCCm), CD10, and vimentin.
  • Eight benign oncocytic tumors (29%) had clear cell features while 6 metastatic RCC (37%) had oncocytic features.
  • Median Fuhrman nuclear grade was 2 in oncocytoma and oncocytosis and 3 both oncocytic carcinoma and metastatic RCC.
  • Mitotic rates were only significantly different between benign oncocytic tumors and metastatic RCC.
  • Seven benign oncocytic tumors (25%) and 5 oncocytic carcinomas (56%) had RCC-like vascular stroma.
  • All primary salivary gland tumors were positive for p63, predominately in basal cell-type distribution.
  • While clinical history and morphology usually are adequate, demonstration of p63 staining can definitively exclude metastatic RCC from the differential diagnosis of similar appearing tumors in salivary glands, namely oncocytoma and oncocytic carcinoma, with 100% specificity and sensitivity.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / metabolism. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Predictive Value of Tests

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Otolaryngol Head Neck Surg. 2002 Jun;126(6):657-62 [12087334.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Adv Anat Pathol. 2002 Sep;9(5):280-9 [12195217.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1598-602 [12352670.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):133-9 [12533521.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1097-9 [12871991.001]
  • [Cites] Lab Invest. 1970 Dec;23(6):567-80 [5530737.001]
  • [Cites] Mich Med. 1971 Jul;70(16):616-8 [5571989.001]
  • [Cites] Laryngoscope. 1973 Jun;83(6):898-905 [4711327.001]
  • [Cites] Laryngoscope. 1981 Apr;91(4):517-9 [6261053.001]
  • [Cites] South Med J. 1981 Sep;74(9):1050-2 [7280750.001]
  • [Cites] Pathol Res Pract. 1986 Dec;181(6):684-92 [3562340.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):862-7 [3402976.001]
  • [Cites] Head Neck. 1989 Mar-Apr;11(2):174-8 [2656583.001]
  • [Cites] Histopathology. 1990 May;16(5):487-93 [2361662.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):514-28 [2031528.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2281-7 [8940996.001]
  • [Cites] Semin Diagn Pathol. 1997 Aug;14(3):203-12 [9279976.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):225-8 [9682986.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Am J Surg Pathol. 2007 Jan;31(1):44-57 [17197918.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Head Neck. 2005 Aug;27(8):696-702 [16021638.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):676-85 [12033955.001]
  • [Cites] Int J Surg Pathol. 2005 Oct;13(4):329-35 [16273188.001]
  • (PMID = 20614263.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2807526
  • [Keywords] NOTNLM ; Metastatic renal cell carcinoma / Oncocytic carcinoma / Oncocytoma / p63
  •  go-up   go-down


6. Motta MP, Athanazio DA, Motta A, Studart E, Athanazio PR: Parietal cell (oncocytic) adenocarcinoma of the stomach in a female patient: superficial spreading and extensive nodal involvement. Int J Surg Pathol; 2008 Oct;16(4):447-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parietal cell (oncocytic) adenocarcinoma of the stomach in a female patient: superficial spreading and extensive nodal involvement.
  • A case of parietal cell (oncocytic) adenocarcinoma in a 62-year-old woman is reported.
  • In the present case, the unusual finding of parietal cell (oncocytic) adenocarcinoma and extensive nodal metastasis in a woman is reported.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis / pathology. Parietal Cells, Gastric / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18387987.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Piana S, Asioli S, Foroni M: Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features. Virchows Arch; 2006 Feb;448(2):228-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic adenocarcinoma of the rectum arising on a villous adenoma with oncocytic features.
  • Rectal adenocarcinoma with diffuse oncocytic features is a very rare lesion, having been reported only once in the English literature.
  • We describe a case of oncocytic adenocarcinoma of the rectum, associated with a villous adenoma, arising on a 66-year-old man.
  • On histological examination, the adenocarcinoma was composed of neoplastic glands lined by a strongly eosinophilic, granular epithelium that deeply infiltrated the rectal wall.
  • Molecular alterations observed in oncocytic changes and their significance with regards to neoplastic transformation are briefly discussed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16450120.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


8. Munitiz V, Martinez-Barba E, Riquelme J, Rodriguez JM, Piñero A, Parrilla P: Elevated basal calcitonin levels in a patient with a hurthle-cell carcinoma of the thyroid and neuroendocrine differentiation: report of a case. Surg Today; 2005;35(5):404-6
Hazardous Substances Data Bank. Calcitonin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated basal calcitonin levels in a patient with a hurthle-cell carcinoma of the thyroid and neuroendocrine differentiation: report of a case.
  • A thyroid nodule with elevated plasma levels of calcitonin is usually suggestive of a medullary thyroid carcinoma (MTC); however, thyroid and extrathyroid conditions have been reported with elevated plasma calcitonin levels in the absence of MTC.
  • Interestingly, histopathological examination revealed a Hurthle-cell carcinoma with positive neuroendocrine (NE) markers such as calcitonin and synapthophysin, but not with chromogranin staining.
  • [MeSH-major] Adenoma, Oxyphilic / blood. Calcitonin / blood. Thyroid Neoplasms / blood. Thyroid Nodule / blood

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864423.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9007-12-9 / Calcitonin
  •  go-up   go-down


9. Yaqub A: Familial Hurthle cell carcinoma of the thyroid: case reports and review of the literature. W V Med J; 2009 Jul-Aug;105(4):23-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial Hurthle cell carcinoma of the thyroid: case reports and review of the literature.
  • OBJECTIVE: To describe case reports of a brother and sister pair with Hurthle cell carcinoma of thyroid.
  • Both had the disease diagnosed in later years of life, had cold nodules for 4-5 years before histological diagnosis, and both had local recurrence following thyroidectomy and postoperative radioiodine ablation.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Thyroid Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585901.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


10. Lallu S, Naran S, Bethwaite P: Fine needle aspiration cytology of unsuspected metastatic hurthle cell carcinoma of the thyroid and its pitfalls: a report of two cases. Diagn Cytopathol; 2007 Jul;35(7):439-43
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of unsuspected metastatic hurthle cell carcinoma of the thyroid and its pitfalls: a report of two cases.
  • We discuss two cases of unsuspected metastatic thyroid carcinoma of Hurthle cell type, presenting as subcutaneous masses in the occipital scalp and supra-acetabular region of the right ilium; clinically suspected to be a lipoma and a vascular tumour, respectively.
  • In case 1, a definitive diagnosis of metastatic Hurthle cell carcinoma was made based on cell block preparation and positive immunohistochemical stains for thyroglobulin and thyroid transcription factor-1.
  • Case 2 was reported as suggesting an oncocytic process, metastatic Hurthle cell lesion.
  • These cases are of interest as the bland cytologic features may lead to an erroneous benign diagnosis.
  • Immunohistochemistry aids the definitive diagnosis of metastatic Hurthle cell carcinoma of thyroid especially when the presence of a previous thyroid lesion is not communicated to the laboratory.
  • [MeSH-major] Adenoma, Oxyphilic / secondary. Biopsy, Fine-Needle. Bone Neoplasms / secondary. Skin Neoplasms / secondary. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580356.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Caloglu M, Yurut-Caloglu V, Altaner S, Huseyinova G, Unlu E, Karagol H, Uzal C: Oncocytic carcinoma of the parotid gland. Onkologie; 2006 Sep;29(8-9):388-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the parotid gland.
  • BACKGROUND: Oncocytic carcinoma is a rare tumor of major salivary glands.
  • Histochemical or electron microscopic confirmation of the oncocytic nature of the tumor cell is needed for differential diagnosis.
  • Malignant oncocytomas have the potential risk of developing distant metastases and demand long term follow-up after therapy.
  • CASE REPORT: A 58-year old man presented with a recurrent mass in the left parotid gland with a prior diagnosis of monomorphic adenoma in the same localization which had been treated by tumor excision in July 2002.
  • CONCLUSION: For an accurate approach in the management of patients, oncocytic adenocarcinoma should be considered in the differential diagnosis of lesions of the parotid gland, most of which are benign.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / therapy. Parotid Neoplasms / pathology. Parotid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16974117.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Al-Khatib K, Sieunarine K, Lindsay I, Smith JR: Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):429-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle cell carcinoma in the abdomen masquerading as a primary ovarian tumor: a case report.
  • Hurthle cell carcinoma, a variant of follicular carcinoma of the thyroid, has been regarded as an aggressive type of differentiated thyroid cancer.
  • It is diagnosed histologically and regarded as a carcinoma by the presence of vascular invasion or capsular invasion.
  • In this case report, a patient with a history of thyroid Hurthle cell carcinoma presented with what seemingly appeared to be a pelvic mass of gynecological origin, with a raised risk-of-malignancy index of 567.
  • They were diagnosed to be secondary lesions of Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma of the thyroid has not been known to be associated with the elevation of CA125 nor has it been known to metastasize to the small bowel and sigmoid colon.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Laparotomy / methods. Lymph Nodes / pathology. Ovariectomy / methods. Postmenopause. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445671.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yuen HK, Cheuk W, Cheng AC, Anh C, Chan N: Malignant oncocytoma of the lacrimal sac as an unusual cause of epiphora. Ophthal Plast Reconstr Surg; 2007 Jan-Feb;23(1):70-2
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant oncocytoma of the lacrimal sac as an unusual cause of epiphora.
  • Incisional biopsy revealed malignant oncocytoma of the lacrimal sac.
  • Patients with malignant oncocytoma may present with simple epiphora in absence of other signs and symptoms such as blood stained tearing or purulent rhinorrhea.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237701.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Batistatou A, Doukas M, Baltogiannis G, Panelos J, Kamina S, Charalabopoulos K, Agnantis NJ: Early gastric carcinoma with oncocytic features and extensive metastases. Pathol Res Pract; 2007;203(7):539-41
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early gastric carcinoma with oncocytic features and extensive metastases.
  • We present the case of a 63-year-old Caucasian woman with early gastric adenocarcinoma, suffering from extensive metastases at the time of initial presentation.
  • Microscopic examination of the gastrectomy specimen revealed an invasive adenocarcinoma with oncocytic features.
  • Interestingly, despite the fact that the carcinoma was pT1, it also was found to be N2, stage IV.
  • The biologic behavior of oncocytic adenocarcinoma of the stomach is still unclear.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17590281.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Namwongprom S, Núñez RF, Yeung HW, Kim EE, Macapinlac HA: Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid. Exp Clin Endocrinol Diabetes; 2007 Nov;115(10):694-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual adrenal metastasis and abdominal carcinomatosis secondary to Hurthle cell carcinoma of the thyroid.
  • Hurthle cell carcinoma (HCC) of the thyroid is an uncommon and relatively rare differentiated thyroid neoplasm.
  • [MeSH-major] Abdominal Neoplasms / radiography. Adenoma, Oxyphilic / radiography. Adrenal Gland Neoplasms / radiography. Carcinoma / radiography. Positron-Emission Tomography. Thyroid Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058606.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. McGinnis M: Metastatic Hurthle cell carcinoma and medical certification. Aviat Space Environ Med; 2007 Nov;78(11):1078-9
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Hurthle cell carcinoma and medical certification.
  • Thyroid carcinoma is the most common malignancy of the endocrine system.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery. Work Capacity Evaluation

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018444.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


17. Lombardi D, Piccioni M, Farina D, Morassi ML, Nicolai P: Oncocytic carcinoma of the maxillary sinus: a rare neoplasm. Eur Arch Otorhinolaryngol; 2006 Jun;263(6):528-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the maxillary sinus: a rare neoplasm.
  • Oncocytic neoplasms are tumors composed of oncocytes (i.e., epithelial cells with a large cytoplasm that is rich in mitochondria).
  • Occurrence of oncocytic carcinoma (or malignant oncocytoma) within the sinonasal tract is an unusual event.
  • We report a rare case of maxillary sinus oncocytic carcinoma occurring in a 45-year-old male.
  • Definitive histology was consistent with oncocytic carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Maxillary Sinus Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16474973.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Colella G, Apicella A, Bove P, Rossiello L, Trodella M, Rossiello R: Oncocytic carcinoma of the accessory lobe of the parotid gland. J Craniofac Surg; 2010 Nov;21(6):1987-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the accessory lobe of the parotid gland.
  • Oncocytic carcinoma is a rare tumor of the parotid gland.
  • The clinical and histologic difficulties in relationship to the diagnosis of a midcheek mass consisting of an unusual tumor are emphasized.
  • [MeSH-major] Adenocarcinoma / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Cheek / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Masseter Muscle / pathology. Oxyphil Cells / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119478.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Katz-Selbst ML, Chhieng DC: Fine-needle aspiration biopsy of recurrent oncocytic carcinoma of parotid gland. Diagn Cytopathol; 2009 Nov;37(11):849-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of recurrent oncocytic carcinoma of parotid gland.
  • His past history was significant for resection of primary oncoctyic carcinoma of the right parotid gland 5 years ago.
  • Fine-needle aspiration biopsy of the right cheek mass was performed and demonstrated oncocytic cells without significant cytologic atypia.
  • On the basis of the past history and comparison of the histology of previously resected specimen, the cytologic impression was consistent with recurrent oncocytic carcinoma of the salivary gland.
  • The cytologic differential diagnosis should include other primary salivary gland neoplasms and metastatic disease.
  • [MeSH-major] Carcinoma / pathology. Neoplasm Recurrence, Local / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526569.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Giordano G, Gabrielli M, Gnetti L, Ferri T: Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features. World J Surg Oncol; 2006;4:54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features.
  • BACKGROUND: Oncocytic carcinoma is an extremely rare neoplasm of the salivary glands.
  • We report a case of oncocytic carcinoma arising in a parotid gland in a 66-year-old female.
  • RESULTS: Frozen sections revealed an infiltrative growth pattern and the diagnosis of a malignant epithelial lesion was made.
  • Thus, the final diagnosis was that of oncocytic carcinoma of parotid gland.
  • CONCLUSION: This neoplasm shows clinical, microscopical, histological and ultrastructural features of oncocytic carcinoma and this must be considered in the differential diagnosis of other proliferations in the parotid gland with abundant granular cytoplasm and metastatic oncocytic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Jan 1;59(1):107-12 [3539304.001]
  • [Cites] J Urol. 1985 May;133(5):762-6 [3886935.001]
  • [Cites] Histopathology. 1997 Nov;31(5):408-11 [9416480.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Oral Oncol. 2003 Feb;39(2):199-203 [12509976.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):61-6 [3422397.001]
  • [Cites] Cancer. 1988 Mar 1;61(5):889-95 [3276393.001]
  • [Cites] Auris Nasus Larynx. 2005 Sep;32(3):305-8 [15869853.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jul;262(7):567-9 [15592856.001]
  • [Cites] HNO. 2001 Feb;49(2):109-17 [11270192.001]
  • (PMID = 16923179.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1564019
  •  go-up   go-down


21. Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M: Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta Otorhinolaryngol Ital; 2009 Dec;29(6):305-11
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hurthle cell tumours of the thyroid. Personal experience and review of the literature.
  • Hurthle cell carcinoma represents about 5% of differentiated thyroid carcinomas.
  • The prognosis of the malignant type of the tumour is still under debate as some Authors have reported that Hurthle cell adenoma occasionally behaves like Hurthle cell carcinoma.
  • Aim of the present study was to evaluate previously reported data and personal experience on the clinical and pathological features of patients affected by Hurthle cell tumour that may predict disease progression and death.
  • From 1992 to 2003, the Authors identified 28 patients affected by Hurthle cell tumour, 9 with Hurthle cell adenoma and 19 with Hurthle cell carcinoma.
  • Mean age of patients affected by adenoma was 49.7 years (range 30-72) vs. 49.3 years (range 15-72) in Hurthle cell carcinoma patients.
  • At histology, 9 adenomas, 5 "minimally invasive" and 14 invasive carcinomas were found.
  • Post-operatively, in Hurthle cell carcinoma patients, TNM staging showed 9 patients with stage I, 5 stage II, 4 stage III and one stage IVa (UICC, 2002).
  • All invasive carcinomas underwent (131)I therapy (91-585 mCi).
  • One Hurthle cell carcinoma patient received external beam radiotherapy.
  • Only one Hurthle cell carcinoma patient showed distant lung metastases at 60 months' follow-up.
  • In conclusion, Hurthle cell carcinoma was not found to present a more aggressive behaviour than follicular carcinoma, when risk factors, including extent of tumour invasion, were taken into account.
  • None of the patients with Hurthle cell adenoma showed a relapse or death caused by the tumour.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2000 Aug;24(8):898-906 [10865033.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):107-15 [10993269.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2616-25 [11352953.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):243-9 [11408821.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):911-7 [11420462.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1160-3 [11571953.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1857-65 [12000737.001]
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):331-5 [12057113.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2178-80 [12461336.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Feb;129(2):207-10 [12578450.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1186-94 [12599224.001]
  • [Cites] Surgery. 2003 Dec;134(6):881-9; discussion 889 [14668719.001]
  • [Cites] Endocr J. 2004 Jun;51(3):265-77 [15256771.001]
  • [Cites] Diagn Cytopathol. 2004 Nov;31(5):307-12 [15468114.001]
  • [Cites] Folia Histochem Cytobiol. 2004;42(3):165-8 [15493577.001]
  • [Cites] Surg Gynecol Obstet. 1974 Oct;139(4):555-60 [4479589.001]
  • [Cites] Mayo Clin Proc. 1984 Dec;59(12):851-5 [6503367.001]
  • [Cites] Surg Gynecol Obstet. 1985 May;160(5):409-13 [3992444.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Oct;61(4):773-8 [2993348.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1613-7 [3948132.001]
  • [Cites] Semin Diagn Pathol. 1985 May;2(2):101-22 [3843689.001]
  • [Cites] Arch Surg. 1988 Jul;123(7):849-54 [3382350.001]
  • [Cites] World J Surg. 1988 Aug;12(4):488-95 [3048000.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):908-11 [2914297.001]
  • [Cites] Mayo Clin Proc. 1991 Jan;66(1):11-22 [1988751.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1944-53 [1913544.001]
  • [Cites] Acta Pathol Jpn. 1992 May;42(5):305-15 [1636432.001]
  • [Cites] Surg Clin North Am. 1995 Jun;75(3):395-403 [7747248.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Oct;80(10):2946-53 [7559879.001]
  • [Cites] Surgery. 1995 Dec;118(6):1131-6; discussion 1136-8 [7491533.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801 [8608779.001]
  • [Cites] Surgery. 1996 Dec;120(6):1000-4; discussion 1004-5 [8957486.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):542-6 [9563543.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):893-910 [9735140.001]
  • [Cites] Surgery. 1998 Dec;124(6):967-74 [9854570.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2638-48 [9874472.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Dec;12(4):329-37 [15536332.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2842-6 [18665423.001]
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):230-4 [18722077.001]
  • [Cites] Otolaryngol Head Neck Surg. 2009 May;140(5):715-9 [19393417.001]
  • [Cites] Diagn Cytopathol. 2009 Aug;37(8):600-6 [19526577.001]
  • (PMID = 20463834.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] Thyroid cancer, Hurthle cell
  • [Other-IDs] NLM/ PMC2868205
  • [Keywords] NOTNLM ; Hurthle cell adenoma / Hurthle cell carcinoma / Thyroid
  •  go-up   go-down


22. Morelli L, Pusiol T, Piscioli F: [Ovarian oxyphilic Sertoli cell tumor: case report and review of the literature]. Pathologica; 2006 Jun;98(3):184-6
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian oxyphilic Sertoli cell tumor: case report and review of the literature].
  • [Transliterated title] Tumore a cellule di Sertoli ossifile dell'ovaio: caso clinico e revisione della letteratura.
  • Ovarian oxyphilic Sertoli cell tumor is a rare neoplasm (only three cases were reported in literature).
  • Pathologist 1 made a diagnosis of endometrioid adenocarcinoma, while Pathologist 2 made the diagnosis of oxyphilic Sertoli cell tumor.
  • He sends the same slides to Pathologist 1, who confirmed his diagnosis.
  • The two different diagnosis set different managements of the lesion for the clinician, but overall they set the pathologist who requested the consultation in a difficult position.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17036948.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Fluorescent Dyes; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  • [Number-of-references] 1
  •  go-up   go-down


23. Rouzbahman M, Serra S, Chetty R: Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy. J Clin Pathol; 2006 Oct;59(10):1039-43
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy.
  • BACKGROUND: The introduction of preoperative chemoradiation into the treatment protocol of rectal adenocarcinomas has affected the microscopical morphology in subsequent resection specimens.
  • AIM: To describe oncocytic change in rectal cancers that have been treated with chemoradiation before surgery.
  • Oncocytic change in this particular clinical context occurs as a reflection of cytotoxic damage or cellular hypoxia induced by chemoradiation resulting in degeneration of the cell and the oncocytic phenotype.
  • Oncocytic change may be an under-recognised histopathological change in rectal cancers receiving preoperative chemoradiation.
  • [MeSH-major] Adenocarcinoma / ultrastructure. Oxyphil Cells / ultrastructure. Rectal Neoplasms / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultrastruct Pathol. 2000 Nov-Dec;24(6):417-22 [11206339.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):221-30 [9500224.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):126-34 [10452578.001]
  • [Cites] Br J Surg. 1999 Sep;86(9):1108-20 [10504363.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):458-65 [11914623.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Ultrastruct Pathol. 2003 Mar-Apr;27(2):87-94 [12746199.001]
  • [Cites] Virchows Arch. 2003 Oct;443(4):579-82 [12955503.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):215-23 [15043311.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Cancer. 1977 Sep;40(3):1330-6 [198093.001]
  • [Cites] Can J Surg. 1982 May;25(3):332-3 [6282429.001]
  • [Cites] Arkh Patol. 1986;48(6):79-81 [3019283.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Int J Gynecol Pathol. 1994 Oct;13(4):290-301 [7814190.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):206-8 [8617466.001]
  • [Cites] Am J Dermatopathol. 1996 Jun;18(3):314-6 [8806968.001]
  • [Cites] Virchows Arch. 1996 Oct;429(2-3):181-3 [8917721.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):871-83 [9255250.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • (PMID = 16467161.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC1861763
  •  go-up   go-down


24. Hu YW, Lin CZ, Li WY, Chang CP, Wang LW: Locally advanced oncocytic carcinoma of the nasal cavity treated with surgery and intensity-modulated radiotherapy. J Chin Med Assoc; 2010 Mar;73(3):166-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced oncocytic carcinoma of the nasal cavity treated with surgery and intensity-modulated radiotherapy.
  • Oncocytic carcinomas of the nasal cavity are extremely rare.
  • An 80-year-old man with a history of nasal oncocytoma had received excision twice previously.
  • Pathological examination revealed oncocytic carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / therapy. Nasal Cavity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20231003.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


25. Abe T, Murakami A, Nakajima N, Inoue T, Ohde S, Miwa M, Ueda Y, Kawabata K, Watanabe K: Oncocytic carcinoma of the nasal cavity with widespread lymph node metastases. Auris Nasus Larynx; 2007 Sep;34(3):393-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the nasal cavity with widespread lymph node metastases.
  • The first case of oncocytic carcinoma which arose from the inferior turbinate of the nasal cavity with orbital invasion through the nasolacrimal canal and widespread lymph node metastases in the neck and face is reported here.
  • We think the oncocytic carcinoma of the nasal cavity may be a high-grade malignancy tumor.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Lymph Nodes / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology. Turbinates / pathology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Diagnosis, Differential. Disease Progression. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Microscopy, Electron. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Orbit / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459629.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW: Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol; 2006 May;34(5):330-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
  • The diagnosis of an adequately sampled thyroid FNA is generally grouped into three categories: benign, malignant, and indeterminate.
  • The latter group usually includes follicular neoplasm, follicular lesion, and sometimes a more specific diagnosis such as Hurthle cell neoplasm or follicular lesion/neoplasm with Hurthle cell change.
  • Whether a FNA diagnosis of Hurthle cell lesion/neoplasm (HLN) denotes a worse clinical outcome than follicular lesion/neoplasm (FLN) remains controversial.
  • A cohort of 303 thyroid FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision diagnosis compared to the FNA diagnosis in order to address this issue.
  • Of this cohort, 87 cases had an FNA diagnosis of HLN while 216 cases had a diagnosis of FLN.
  • Upon excision, the FNA diagnosis of HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12 follicular adenoma (14%) and 34 cases of Hurthle cell adenoma (39%)), and 27 cases of carcinoma (31%, 12 papillary carcinoma and 15 Hurthle cell carcinoma).
  • The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of follicular adenoma (33.8%), one case of granular cell tumor, and 60 cases of carcinoma (27.8%, 46 papillary carcinoma, 12 follicular carcinoma, and 1 Hurthle cell carcinoma and 1 parathyroid carcinoma) upon excision.
  • There is no significant difference in predicting cancer between the two cytology diagnosis groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771).
  • When sorting all the cases by the surgical diagnosis, while comparable for age at diagnosis, the cancer group having the higher proportion of male patients than the non-cancer group (28.7% versus 16.7%, P = 0.0259).
  • Hurthle cell carcinoma patients are typically older than patients with other cancer diagnoses (59 versus 44, P = 0.0077).
  • Our results suggest that an FNA diagnosis of HLN does not predict more malignancy than FLN.
  • Males and older patients with a HLN FNA diagnosis carry a higher risk of Hurthle cell carcinoma upon thyroidectomy.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Goiter, Nodular / pathology. Goiter, Nodular / surgery. Humans. Hyperplasia / pathology. Hyperplasia / surgery. Male. Middle Aged. Prognosis. Thyroid Nodule / pathology. Thyroid Nodule / surgery. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604553.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL: Variables predicting distant metastases in thyroid cancer. Laryngoscope; 2005 Apr;115(4):661-7
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic type was Hurthle cell carcinoma in 3, follicular in 3, papillary in 19, and 5 patients had focal anaplasia either in the primary site or regional metastases.
  • The median time to diagnosis of distant metastases was 3 months.
  • [MeSH-major] Carcinoma / secondary. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / secondary. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / secondary. Age Factors. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Papillary / pathology. Carcinoma, Papillary / secondary. Female. Follow-Up Studies. Forecasting. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Risk Factors. Sex Factors. Survival Rate. Thyroglobulin / analysis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805877.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


28. Troncone G, Iaccarino A, Russo M, Palmieri EA, Volante M, Papotti M, Viglietto G, Palombini L: Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. J Clin Pathol; 2007 Apr;60(4):377-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.
  • However, the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma expresses more p27 than benign oxyphilic lesions do.
  • METHODS: Because high levels of cyclin D3 lead to p27 accumulation in cell lines and clinical samples of thyroid cancer, the immunocytochemical pattern of cyclin D3 in oxyphilic (n = 47) and non-oxyphilic (n = 70) thyroid neoplasms was investigated.
  • The expression of cyclin D3 and p27 was significantly higher in the oxyphilic variant of follicular carcinomas than in non-oxyphilic carcinomas (p<0.001).
  • In co-immunoprecipitation experiments, the level of p27-bound cyclin D3 was much higher in oxyphilic neoplasias than in normal thyroids and other thyroid tumours.
  • CONCLUSION: These results show that increased p27 expression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma results from cyclin D3 overexpression.
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / metabolism. Adenoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cyclin D3. Humans. Immunoprecipitation. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Mar;128(3):253-7 [11886339.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):1014-9 [11007042.001]
  • [Cites] J Clin Pathol. 2003 Aug;56(8):587-91 [12890807.001]
  • [Cites] Mod Pathol. 2003 Sep;16(9):886-92 [13679452.001]
  • [Cites] Oncogene. 2003 Oct 23;22(48):7576-86 [14576819.001]
  • [Cites] J Histochem Cytochem. 1982 Nov;30(11):1114-22 [6183312.001]
  • [Cites] Mod Pathol. 1998 Feb;11(2):169-74 [9504687.001]
  • [Cites] J Pathol. 1998 Jun;185(2):159-66 [9713342.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):735-9 [9720501.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):678-85 [10366150.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] Blood. 1999 Jul 15;94(2):765-72 [10397744.001]
  • [Cites] J Clin Invest. 1999 Oct;104(7):865-74 [10510327.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):242-8 [15671552.001]
  • [Cites] Diagn Cytopathol. 2000 Aug;23(2):77-81 [10888749.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3614-20 [10999753.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1038-43 [12379749.001]
  • (PMID = 16798934.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCND3 protein, human; 0 / Cyclin D3; 0 / Cyclins; 0 / Neoplasm Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC2001124
  •  go-up   go-down


29. Lee JS, Choi JH, Oh YH: Oncocytic carcinoma arising in the submandibular gland with disseminated bone metastases. South Med J; 2009 Jun;102(6):659-62
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma arising in the submandibular gland with disseminated bone metastases.
  • Oncocytic carcinoma of the head and neck is a very rare neoplasm.
  • Only 11 cases of oncocytic carcinoma of the submandibular gland have been reported, and no cases have shown distant bone metastasis.
  • The submandibular gland and bone marrow biopsies were consistent with oncocytic carcinoma.
  • Our case is the first report of oncocytic carcinoma of the submandibular gland with disseminated bone metastases.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Bone Neoplasms / secondary. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Male. Neoplasm Metastasis / pathology. Oxyphil Cells / pathology. Submandibular Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434038.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Ponikiewska D, Szcześniak-Kłusek B, Stobiecka E, Jaworska M, Lange D: [Oxyphilic and follicular thyroid tumors--the correlation between the cytopathologic diagnosis and the histopathologic examination]. Endokrynol Pol; 2006;57 Suppl A:7-11
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxyphilic and follicular thyroid tumors--the correlation between the cytopathologic diagnosis and the histopathologic examination].
  • INTRODUCTION: Fine needle aspiration biopsy (FNAB) of the thyroid nodules generally allows to make the diagnosis and to choose the proper clinical management.
  • In about 10% of cases cytopathologic features do not differentiate unequivocally benign and malignant lesions.
  • In these cases the cytopathologic diagnosis of follicular tumor (FT) or oxyphilic tumor (OT) is most often made.
  • MATERIALS AND METHODS: From 2001 to 2002 in our Department of Pathology the cytopathologic diagnosis of FT and OT was made in 102 and 25 cases respectively.
  • RESULTS: Histopathological diagnosis of neoplasm was made in 48.7% (19/39) FT and 42% (8/19) OT.
  • The risk of carcinoma was 12.8% in FT and 16% in OT group (surgical treated cases only).
  • CONCLUSIONS: These results show how difficult the diagnostics of follicular lesions in FNAB could be because of the frequent overlapping of the cytological features of benign and malignant lesions.
  • Diagnosis of follicular tumor does not mean carcinoma.
  • The use of follicular/ oxyphilic tumor in cytological diagnostic instead of follicular neoplasm seems more advisable.
  • [MeSH-major] Adenocarcinoma / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091450.001).
  • [ISSN] 2299-8306
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


31. ul Haq RN, Khan BA, Chaudhry IA: Prevalence of malignancy in goitre--a review of 718 thyroidectomies. J Ayub Med Coll Abbottabad; 2009 Oct-Dec;21(4):134-6
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prevalence of papillary and follicular carcinoma was 33.33% each.
  • Anaplastic carcinoma was found in 23.81% of patients followed by Hurthle cell carcinoma in 9.53% of patients.
  • Prevalence of follicular carcinoma and anaplastic carcinoma is relatively higher in our country due to high incidence of iodine deficiency goitre.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / pathology. Child. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Prospective Studies. Thyroidectomy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21067046.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


32. Stolnicu S, Preda O, Dohan M, Puscasiu L, García-Galvis OF, Nogales FF: Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change. Int J Gynecol Pathol; 2008 Oct;27(4):521-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoglandular hepatoid differentiation in endometrioid carcinoma of the ovary simulates oxyphilic cell change.
  • A 42-year-old patient had a stage III ovarian endometrioid adenocarcinoma with areas of hepatoid carcinoma (HC) of clear cell and eosinophilic pseudoglandular type that was difficult to differentiate from endometrioid carcinoma of oxyphilic type and sex cord-stromal tumor.
  • Immunohistochemically, endometrioid adenocarcinoma was positive for CA125, estrogen and progesterone receptors, CAM5.2, cytokeratin (CK) 7 and 19, and vimentin.
  • HC areas were positive for hep par1, polyclonal carcinoembryonic antigens, CD10, alpha-fetoprotein, epithelial membrane antigens, and antimitochondrial antibodies and shared with endometrioid carcinoma focal CK7, and constant positive CK19, CAM5.2, and progesterone receptors.
  • In the differential diagnosis, a hepatic immunophenotype of oxyphilic, mitochondriae-rich areas (demonstrated by antimitochondrial antibodies) was identified by HC specific (hep par1) and characteristic markers: canalicular, cytoplasmic and membranous polyclonal carcinoembryonic antigens, CD10 patterns, and alpha-fetoprotein).
  • The partial preservation of an endometrioid immunophenotype in HC (positive CK7 and 19 and progesterone receptors) would support an origin from endometrioid carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Carcinoma, Hepatocellular / pathology. Cell Differentiation / physiology. Female. Humans. Immunohistochemistry. Oxyphil Cells / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753970.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Mizutari K, Naganishi H, Tanaka Y: Oncocytic carcinoma in the submandibular gland: report of a case based on anti-mitochondrial immunohistochemical observations. Auris Nasus Larynx; 2005 Sep;32(3):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma in the submandibular gland: report of a case based on anti-mitochondrial immunohistochemical observations.
  • Oncocytic carcinoma arising in the submandibular gland is a very rare tumor that has only previously been reported in nine cases.
  • This paper describes an additional case of oncocytic carcinoma in the right submandibular gland.
  • Consequently, we diagnosed the mass as oncocytic carcinoma.
  • Usually, electron microscopy is necessary to diagnose oncocytic lesions, but the paraffin-embedded tissue was not suitable for electron microscopy.
  • Immunohistochemistry using an anti-mitochondrial antibody was found to be useful and helpful for the diagnosis of oncocytic lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Immunohistochemistry / methods. Mitochondria / immunology. Submandibular Gland Neoplasms / diagnosis. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Antibodies. Cell Nucleus / pathology. Cytoplasm / pathology. Humans. Magnetic Resonance Imaging. Male. Microscopy, Electron. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869853.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies
  •  go-up   go-down


34. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Slough CM, Randolph GW: Workup of well-differentiated thyroid carcinoma. Cancer Control; 2006 Apr;13(2):99-105
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Workup of well-differentiated thyroid carcinoma.
  • BACKGROUND: Well-differentiated thyroid carcinoma (WDTC) includes three main entities: papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and Hurthle cell carcinoma (HCC).
  • A thorough knowledge of the natural history and presentation of these carcinomas is vital to the thyroid surgeon.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Cell Differentiation. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Preoperative Care. Thyroidectomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735983.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 72
  •  go-up   go-down


36. Guclu E, Oghan F, Ozturk O, Alper M, Egeli E: A rare malignancy of the parotid gland: oncocytic carcinoma. Eur Arch Otorhinolaryngol; 2005 Jul;262(7):567-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare malignancy of the parotid gland: oncocytic carcinoma.
  • Oncocytic carcinomas are uncommon; they represent 11% of all oncocytic salivary gland neoplasms, 0.5% of all epithelial salivary gland malignancies and 0.18% of all epithelial salivary gland tumors.
  • As oncocytes and atypical cells were seen at the cytologic examination of a fine-needle aspiration biopsy, this finding suggested a malignant epithelial tumor.
  • The result of the pathologic examination was oncocytic carcinoma regarding histopathologic and immunohistochemical findings and especially the invasive growth pattern.
  • The prognosis of oncocytic carcinomas is not well known because of their low incidence.
  • Further investigation of the prognosis of patients with oncocytic carcinoma of the parotid gland is warranted as more cases are reported.
  • [MeSH-major] Carcinoma / pathology. Oxyphil Cells / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592856.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Sugiyama T, Nakagawa T, Narita M, Nakamura S, Inui M, Tagawa T: Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies. Oral Dis; 2006 May;12(3):324-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pedunculated oncocytic carcinoma in buccal mucosa: immunohistochemical and ultrastructural studies.
  • PURPOSE: In this study we evaluated pedunculated oncocytic carcinoma (OC) in the buccal mucosa via immunohistochemical and ultrastructural studies.
  • An incision biopsy revealed the diagnosis of oncocytic tumor, and enucleation was performed.
  • RESULTS: Histopathology results revealed that the tumor consisted of oncocytic cells, characterized by eosinophilic and granular cytoplasm, and atypical nuclei.
  • Electron microscopy revealed numerous dilated cytoplasmic mitochondria, and the cell contours and nucleic shapes of tumor cells were often irregular.
  • CONCLUSIONS: Because the histopathologic features of OC are similar to those of benign oncocytoma, the diagnosis of OC must be confirmed by a combination of clinical and ultrastructural characteristics.
  • [MeSH-major] Adenocarcinoma / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700744.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


38. Choi YL, Kim MK, Suh JW, Han J, Kim JH, Yang JH, Nam SJ: Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas. J Korean Med Sci; 2005 Oct;20(5):853-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
  • To examine the immunohistochemical alterations associated with the histological dedifferentiation of thyroid carcinomas, we performed staining for HBME-1, high molecular weight cytokeratin (HCK), CK 19, thyroid transcription factor-1 (TTF-1) and E-cadherin (E-CD) on 125 various types of thyroid carcinomas.
  • The HBME-1 staining was strong and diffuse in follicular carcinoma (FC), papillary carcinoma (PC), and poorly differentiated carcinoma (PDC), while it was rare in undifferentiated carcinoma (UC) as well as in benign lesions.
  • Strong, diffuse staining for CK19 and HCK was predominantly found in PC, and these markers were not much found in other carcinomas.
  • TTF-1 uniformly stained the tumor cells of all cases of PC, FC and Hurthle cell carcinoma (HC) and 42% of the PDC, while there was only focal staining in one case of the UC.
  • These results suggest that HBME-1 may be a marker for well-differentiated carcinomas while CK19 and HCK are phenotypic markers for papillary carcinoma.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Oct;30(10):1166-71 [10534163.001]
  • [Cites] Mod Pathol. 2000 May;13(5):570-6 [10824930.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):42-8 [10937048.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):55-60 [12746563.001]
  • [Cites] Histopathology. 2003 Jun;42(6):580-7 [12786894.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):319-22 [14974863.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4987-93 [8402689.001]
  • [Cites] Endocrinology. 1995 Jul;136(7):3113-9 [7789339.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2168-72 [7608273.001]
  • [Cites] Endocrinology. 1995 Oct;136(10):4672-80 [7664688.001]
  • [Cites] Cell Growth Differ. 1996 Feb;7(2):251-61 [8822209.001]
  • [Cites] Int J Cancer. 1997 Jan 6;70(1):32-8 [8985087.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2501-7 [9192832.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):668-74 [9237176.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):93-7 [9484636.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] J Pathol. 1998 Jul;185(3):267-72 [9771480.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1811-5 [10213482.001]
  • [Cites] J Korean Med Sci. 2005 Feb;20(1):98-104 [15716612.001]
  • (PMID = 16224162.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / HBME-1 antigen; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2779285
  •  go-up   go-down


39. Choi YJ, Yun JS, Kim DH: Clinical and ultrasound features of cytology diagnosed follicular neoplasm. Endocr J; 2009;56(3):383-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and ultrasound features of cytology diagnosed follicular neoplasm.
  • The purpose of this study was to identify clinical and ultrasound (US) features of malignancy in patients using cytological results of follicular neoplasm (FN) in the thyroid.
  • Patient histopathology, age, sex, tumor size, and US characteristics and the color flow pattern of the lesions were analyzed and compared between benign and carcinomas.
  • Twenty five (21.9%) of the 114 FN were found to be follicular carcinomas (FC); 15 minimally invasive FC, 4 widely invasive FC, and 6 FVPTC.
  • Benign included 78 FA, 8 atypical FA, and 3 Hurthle cell adenomas.
  • Color Doppler flow pattern of FN with other clinicopathological factors should be carefully considered when predicting the malignant potential of FN.
  • [MeSH-major] Adenocarcinoma, Follicular / ultrasonography. Thyroid Neoplasms / ultrasonography
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adult. Aged. Female. Humans. Male. Middle Aged. Thyroid Gland / pathology. Thyroid Gland / ultrasonography. Ultrasonography, Doppler, Color

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19164864.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Ghofrani M, Sosa JA, Ocal IT, Angeletti C: Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report. Acta Cytol; 2006 Sep-Oct;50(5):560-2
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma: a case report.
  • BACKGROUND: Poorly differentiated oxyphilic (Hürthle cell) carcinomas are a more recently described variant of poorly differentiated thyroid carcinoma and are characterized by a prominent Hürthle cell component in a solid or trabecular arrangement.
  • Clinically, poorly differentiated oxyphilic carcinomas behave more aggressively as compared to classic Hürthle cell carcinomas, which have a predominantly follicular pattern.
  • Fine needle aspiration biopsy of the mass yielded extremely cellular smears with a dual population of medium-sized follicular cells and numerous Hürthle cells.
  • Subsequent thyroidectomy confirmed the malignant nature of this Hürthle cell-rich tumor, warranting a diagnosis of poorly differentiated oxyphilic (Hürthle cell) thyroid carcinoma.
  • CONCLUSION: Poorly differentiated oxyphilic thyroid carcinoma is an aggressive variant of Hürthle cell carcinomas and must enter the differential diagnosis when fine needle aspiration biopsy of a radiologically aggressive thyroid mass yields extremely hypercellular smears with a prominent Hürthle cell component.
  • [MeSH-major] Adenocarcinoma / diagnosis. Epithelial Cells / pathology. Lung Neoplasms / diagnosis. Thyroid Gland / pathology. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Disease Progression. Goiter, Nodular / complications. Goiter, Nodular / drug therapy. Goiter, Nodular / radiotherapy. Humans. Iodine Radioisotopes / therapeutic use. Male. Neoplasm Invasiveness. Thyroidectomy. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17017447.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


41. Bernardini FP, Orcioni GF, Croxatto JO: Oncocytic carcinoma of the lacrimal gland in a patient with neurofibromatosis. Ophthal Plast Reconstr Surg; 2010 Nov-Dec;26(6):486-8
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic carcinoma of the lacrimal gland in a patient with neurofibromatosis.
  • Oncocytic carcinoma (OCA) is rare, and although its occurrence in the lacrimal gland has been documented, clinical and histologic data are lacking.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Neurofibromatoses / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20700068.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Foschini MP, Krausz T: Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential. Semin Diagn Pathol; 2010 Feb;27(1):77-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
  • The clinicopathologic spectrum ranges from benign to malignant but there are important differences as compared with those of their salivary counterpart.
  • In the breast, benign adenomyoepithelioma is recognized in addition to malignant one, whereas in the salivary gland a histologically similar tumor is designated as epithelial-myoepithelial carcinoma without a separate benign subgroup.
  • Mammary adenoid cystic carcinoma is a low-grade neoplasm compared with its salivary equivalent.
  • It is also important to appreciate that in contrast to "triple negative" conventional breast carcinomas with aggressive course, most salivary-type malignant breast neoplasms behave in a low-grade manner.
  • Well established examples of this group include pleomorphic adenoma, adenomyoepithelioma, and adenoid cystic carcinoma.
  • Key examples include mucoepidermoid carcinoma and acinic cell carcinoma.
  • The number of cases of salivary gland-type mammary neoplasms in the published data is constantly increasing but some of the rarest subtypes like polymorphous low-grade adenocarcinoma and oncocytic carcinoma are "struggling" to become clinically relevant entities in line with those occurring more frequently in salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / metabolism. Breast Neoplasms / pathology. Neoplasms, Complex and Mixed / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adenomyoepithelioma / metabolism. Adenomyoepithelioma / pathology. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Male. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306833.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


43. Rubello D, Pelizzo MR, Casara D, Piotto A, Toniato A, Fig L, Gross M: Radio-guided surgery for non-131I-avid thyroid cancer. Thyroid; 2006 Nov;16(11):1105-11
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 33 papillary (one "tall" cell variant), 2 follicular, and 2 Hürthle cell cancers.
  • [MeSH-major] Carcinoma, Papillary / radionuclide imaging. Carcinoma, Papillary / surgery. Radiosurgery / methods. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Follicular / radionuclide imaging. Adenocarcinoma, Follicular / secretion. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / secretion. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Female. Humans. Iodine Radioisotopes. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Neoplasm Recurrence, Local / surgery. Radiopharmaceuticals. Technetium Tc 99m Sestamibi. Thyroglobulin / blood

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123337.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9010-34-8 / Thyroglobulin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


44. Cheung C, Vesey D, Cotterill A, Douglas M, Gobe G, Nicol D, Johnson D: Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. Int J Urol; 2005 Jan;12(1):17-28
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
  • BACKGROUND: The purpose of the present paper was to describe the pattern of expression of insulin-like growth factor (IGF-I) and its regulatory binding proteins (IGFBP) in renal cell carcinoma (RCC).
  • METHODS: The expressions of mRNA and protein for various IGF members were assessed in 24 paired normal and malignant human renal tissues (16 clear cell and 8 papillary RCC) using semiquantitative reverse transcription-polymerase chain reaction and immunohistochemistry.
  • Paired tissue samples were also obtained from six patients with oncocytoma in order to compare the specificity of changes in IGF/IGFBP expression between tumors derived from proximal (RCC) and distal (oncocytoma) tubular epithelium.
  • RESULTS: Clear cell RCC were characterized by significant increases in the mRNA expression of IGF-I, IGFBP-3 and IGFBP-6 while papillary RCC exhibited down-regulated expression of IGF-I, IGFBP-4 and IGFBP-5.
  • Semiquantitative assessment of immunohistochemical staining demonstrated significant increases in epithelial associated IGF-I and IGFBP-3 in clear cell RCC, increased IGFBP-5 protein in papillary RCC and no significant changes in IGF/IGFBP protein expression in oncocytoma.
  • This altered expression is differentially regulated according to the histologic subtype of RCC, and suggests that the IGF/IGFBP axis may play an important role in determining the malignant phenotype of RCC.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Carcinoma, Papillary / metabolism. Carcinoma, Renal Cell / metabolism. Insulin-Like Growth Factor I / metabolism. Kidney Neoplasms / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. Down-Regulation. Female. Humans. Immunohistochemistry. Insulin-Like Growth Factor Binding Proteins / genetics. Insulin-Like Growth Factor Binding Proteins / metabolism. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661050.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


45. Zamecnik M, Sokol L, Michal M: Low-grade metaplastic adenocarcinoma (carcinosarcoma) of the uterus: report of an unusual case. Ann Diagn Pathol; 2005 Dec;9(6):335-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade metaplastic adenocarcinoma (carcinosarcoma) of the uterus: report of an unusual case.
  • An unusual low-grade metaplastic carcinoma (müllerian carcinosarcoma) of the uterine corpus occurring in a 45-year-old woman is presented.
  • The epithelial component was composed of low-grade endometrioid glands that focally showed an unusual oxyphilic change of the cytoplasm.
  • An invasive marginal zone of the tumor showed endometrioid adenocarcinoma pattern without any stromal component.
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Female. Humans. Metaplasia / pathology. Middle Aged. Myometrium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308164.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Rogers CG, Singh A, Blatt AM, Linehan WM, Pinto PA: Robotic partial nephrectomy for complex renal tumors: surgical technique. Eur Urol; 2008 Mar;53(3):514-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology confirmed clear-cell renal cell carcinoma (n=3), hybrid oncocytic tumor (n=2), chromophobe renal cell carcinoma (n=2), and oncocytoma (n=1).
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / surgery. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / surgery. Adult. Aged. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / surgery. Equipment Design. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed. Video Recording

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 2005 May;19(4):441-5; discussion 445 [15910252.001]
  • [Cites] Urology. 2005 Jun;65(6):1086-9 [15913733.001]
  • [Cites] Urology. 2005 Jul;66(1):45-9 [15992879.001]
  • [Cites] World J Urol. 2006 Jun;24(2):171-9 [16544167.001]
  • [Cites] Eur Urol. 2007 Jan;51(1):186-91; discussion 191-2 [16822607.001]
  • [Cites] J Urol. 2007 Jan;177(1):70-4; discussion 74 [17162003.001]
  • [Cites] BJU Int. 2005 Feb;95(3):377-83 [15679798.001]
  • [Cites] Urology. 2004 Nov;64(5):914-8 [15533477.001]
  • [Cites] J Urol. 1991 Aug;146(2):278-82 [1830346.001]
  • [Cites] Am J Surg. 2004 Oct;188(4A Suppl):45S-51S [15476651.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1264-6 [15371820.001]
  • [Cites] J Urol. 2004 Sep;172(3):871-3 [15310986.001]
  • [Cites] J Urol. 2005 Sep;174(3):850-3; discussion 853-4 [16093968.001]
  • [Cites] J Urol. 2006 Jul;176(1):36-9 [16753361.001]
  • [CommentIn] Eur Urol. 2008 Mar;53(3):521-2 [17961911.001]
  • [CommentIn] Eur Urol. 2008 Mar;53(3):522-3 [17961908.001]
  • (PMID = 17961910.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006659-25
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS65236; NLM/ PMC2644902
  •  go-up   go-down


47. Raef H, Alfadhli E, Al-Hajjaj A, Malabu UH, Al-Sobhi S, Rifai A, Al Nuaim A: High rate of persistent/recurrent disease among patients with differentiated thyroid cancer in Saudi Arabia: factors affecting nonremission. Ann Saudi Med; 2008 Jul-Aug;28(4):277-81
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillary thyroid cancer was found in 76%, the follicular variant in 14%, other variants (tall cell and sclerosing types) in 2%, Hurthle cell carcinoma in 4%, and pure follicular thyroid cancer in 4%.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596397.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


48. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM: Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer; 2008 Jul 1;113(1):48-56
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
  • BACKGROUND: Radioactive iodine-refractory (RAIR) 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) positive thyroid carcinomas represent the major cause of deaths from thyroid carcinomas (TC) and are therefore the main focus of novel target therapies.
  • However, to the authors' knowledge, the histology of FDG-PET-positive RAIR metastatic thyroid carcinoma has not been described to date.
  • Poorly differentiated thyroid carcinomas (PDTC) were defined on the basis of high mitotic activity (> or =5 mitoses/10 high-power fields) and/or tumor necrosis.
  • Other types of carcinomas were defined by conventional criteria.
  • Histologic characterization of the metastasis/recurrence in 70 patients revealed that 47.1% (n = 33 patients) had PDTC, 20% (n = 14 patients) had the tall cell variant (TCV) of papillary thyroid carcinoma, 22.9% (n = 16 patients) had well-differentiated papillary thyroid carcinoma (WDPTC), 8.6% (n = 6 patients) had Hurthle cell carcinoma (HCC), and 1.4% (n = 1 patient) had anaplastic carcinomas.
  • Approximately 68% of the PDTC primary tumors were initially classified by the primary pathologist as better-differentiated tumors on the basis of the presence of papillary and/or follicular architecture or the presence of typical PTC nuclear features.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18484584.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Arcinas A, Yen TY, Kebebew E, Macher BA: Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res; 2009 Aug;8(8):3958-68
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns.
  • Cell surface proteins have been shown to be effective therapeutic targets.
  • Thus, identification of cell surface and secreted proteins has been a prime area of interest in the proteomics field.
  • Most cell surface and secreted proteins are known to be glycosylated, and therefore, a proteomics strategy targeting these proteins was applied to obtain proteomic profiles from various thyroid cancer cell lines that represent the range of thyroid cancers of follicular cell origin.
  • In this study, we oxidized the carbohydrates of secreted proteins and those on the cell surface with periodate and isolated them via covalent coupling to hydrazide resin.
  • Thyroid cancer cell lines derived from papillary thyroid cancer (TPC-1), follicular thyroid cancer (FTC-133), Hurthle cell carcinoma (XTC-1), and anaplastic thyroid cancer (ARO and DRO-1) were evaluated.
  • An average of 150 glycoproteins were identified per cell line, of which more than 57% are known cell surface or secreted glycoproteins.
  • In addition to glycoproteins that are commonly expressed by all of the cell lines, we identified others that are only expressed in the more well-differentiated thyroid cancer cell lines (follicular, Hurthle cell and papillary), or by cell lines derived from undifferentiated tumors that are uniformly fatal forms of thyroid cancer (i.e., anaplastic).

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. SODIUM M-PERIODATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Matrix Biol. 2006 Sep;25(7):443-56 [16934444.001]
  • [Cites] Exp Oncol. 2007 Mar;29(1):54-60 [17431390.001]
  • [Cites] Mol Cancer Res. 2007 Jun;5(6):553-67 [17579117.001]
  • [Cites] J Pathol. 2007 Aug;212(4):411-9 [17573672.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6777-85 [17638889.001]
  • [Cites] Anal Chem. 2007 Aug 1;79(15):5826-37 [17591751.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1666-77 [17727684.001]
  • [Cites] Dev Biol. 2007 Oct 15;310(2):291-303 [17822691.001]
  • [Cites] Biophys J. 2008 Feb 15;94(4):1326-40 [17933878.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):818-23 [18212751.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1572-80 [18316623.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1313-24 [18257091.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):194-200 [18353626.001]
  • [Cites] Mol Cell Proteomics. 2008 May;7(5):825-44 [17913849.001]
  • [Cites] Nat Rev Immunol. 2008 Aug;8(8):577-80 [18617884.001]
  • [Cites] Jpn J Clin Oncol. 2008 Aug;38(8):528-33 [18664479.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):4079-88 [18665625.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41 [18713817.001]
  • [Cites] J Biol Chem. 2008 Nov 21;283(47):32802-11 [18718903.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1215-33 [18217975.001]
  • [Cites] Mol Cell Proteomics. 2009 Feb;8(2):287-301 [18923192.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2840-52 [15837731.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Electrophoresis. 2002 Sep;23(18):3205-16 [12298092.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Nat Biotechnol. 2003 Jun;21(6):660-6 [12754519.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6524-36 [14528277.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(20):2310-6 [14558131.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:397-422 [14570575.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11222-6 [1722323.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1991-6 [8364879.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2808-17 [7514955.001]
  • [Cites] Endocr Rev. 1999 Apr;20(2):207-39 [10204118.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Mol Cancer. 2004 Nov 17;3:31 [15548330.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1713-21 [15755992.001]
  • [Cites] Thyroid. 2005 Sep;15(9):1011-20 [16187909.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Oct;6(10):801-11 [16314869.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2070-80 [16335952.001]
  • [Cites] Surgery. 2005 Dec;138(6):1102-9; discussion 1109-10 [16360397.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):226-33 [16263699.001]
  • [Cites] J Pathol. 2006 Mar;208(4):453-61 [16470907.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):659-67 [16256984.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):453-64 [16474910.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2918-22 [16540638.001]
  • [Cites] Histopathology. 2006 Apr;48(5):612-4 [16623792.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):845-57 [16467180.001]
  • [Cites] Cancer Control. 2006 Apr;13(2):99-105 [16735983.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] Cancer. 2006 Jun 15;106(12):2592-7 [16688775.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1151-63 [16777604.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):18257-63 [16648631.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1638-47 [16646078.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):485-9 [16930327.001]
  • [Cites] Surg Oncol. 2006 Jul;15(1):43-55 [16950080.001]
  • [Cites] Cesk Patol. 2006 Jul;42(3):120-4 [16955558.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19530676.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / MD000544-06; United States / NIGMS NIH HHS / GM / R25 GM048972; United States / NIMHD NIH HHS / MD / P20 MD000544; United States / NIMHD NIH HHS / MD / P20 MD000544-06; United States / NIGMS NIH HHS / GM / GM048972
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Hydrazines; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 10450-60-9 / Periodic Acid; B45A1BUM4Q / metaperiodate; EC 3.5.1.52 / Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase
  • [Other-IDs] NLM/ NIHMS132564; NLM/ PMC2735218
  •  go-up   go-down


50. Bonora E, Porcelli AM, Gasparre G, Biondi A, Ghelli A, Carelli V, Baracca A, Tallini G, Martinuzzi A, Lenaz G, Rugolo M, Romeo G: Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res; 2006 Jun 15;66(12):6087-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III.
  • Oncocytic tumors are characterized by cells with an aberrant accumulation of mitochondria.
  • To assess mitochondrial function in neoplastic oncocytic cells, we studied the thyroid oncocytic cell line XTC.UC1 and compared it with other thyroid non-oncocytic cell lines.
  • Osteosarcoma-derived transmitochondrial cell hybrids (cybrids) carrying XTC.UC1 mitochondrial DNA (mtDNA) were generated to discriminate whether the energetic failure depended on mitochondrial or nuclear DNA mutations.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / metabolism. DNA, Mitochondrial / genetics. Electron Transport Complex I / genetics. Electron Transport Complex III / genetics. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Bone Neoplasms / enzymology. Bone Neoplasms / genetics. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Cell Line, Tumor. Cell Survival / physiology. Humans. Osteosarcoma / enzymology. Osteosarcoma / genetics. Osteosarcoma / metabolism. Osteosarcoma / pathology. Oxidative Phosphorylation. Reactive Oxygen Species / metabolism


51. Bell D, Luna MA: Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm. Ann Diagn Pathol; 2009 Jun;13(3):201-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Warthin adenocarcinoma: analysis of 2 cases of a distinct salivary neoplasm.
  • Carcinomas arising in or from the epithelial component of preexisting parotid Warthin tumors (WTs) are rare; the other histologic types of carcinoma found to arise from WTs are adenocarcinoma not otherwise specified, undifferentiated, mucoepidermoid, squamous cell, and oncocytic.
  • We have designated this neoplasm "Warthin adenocarcinoma" (WA).
  • Anderson Cancer Center for cases of malignant WT and salivary adenocarcinoma not otherwise specified diagnosed from January 1, 1985, through December 31, 2006, and evaluated patients' medical records and pathologic material.
  • Histologically, the tumors were composed of bilayered duct-like structures: The inner layer was formed by a single row of columnar oxyphilic cells expressing CK7, CK14, CK18, and AMA.
  • A residual WT with transition to carcinoma was identified in both cases.
  • Warthin adenocarcinoma is a unique salivary gland carcinoma representing the malignant epithelial counterpart of WT.
  • [MeSH-major] Adenocarcinoma / pathology. Adenolymphoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433301.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Park HJ, Jang KT, Heo JS, Choi YL, Han J, Kim SH: A potential case of intraductal tubulopapillary neoplasms of the bile duct. Pathol Int; 2010 Sep;60(9):630-5
MedlinePlus Health Information. consumer health - Bile Duct Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lung tumor was an adenocarcinoma, and the bile duct tumor showed poorly differentiated carcinoma with eosinophilic cytoplasm.
  • Lung lobectomy and hemihepatectomy were performed under the impression of double primary neoplasms of the lung adenocarcinoma and oncocytic variant of the biliary papillary tumor.
  • Eosinophilic cytoplasm of the bile duct tumor was not oncocytic cytoplasm but pyknotic change due to necrosis.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712650.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


53. Heikkilä A, Siironen P, Hagström J, Heiskanen I, Sankila R, Louhimo J, Haglund C, Arola J: Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy. APMIS; 2010 Nov;118(11):846-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy.
  • Thyroid follicular neoplasms are the most common tumors of the thyroid.
  • The criterion for their malignancy is evidence of capsular or vascular invasion, which makes preoperative diagnosis difficult.
  • The poorly differentiated thyroid carcinoma entity was introduced by World Health Organization in its 2004 classification with an incidence still poorly known.
  • We found 356 follicular neoplasms treated between 1990 and 2006.
  • Among these tumor patients, adenomas were more common in women than in men (3.6:1), but carcinomas differed little with respect to gender (1.2:1).
  • All follicular carcinomas (n=39), atypical adenomas (n=6), and oxyphilic adenomas (n=15) were included in the study, as well as 30 consecutive conventional follicular adenomas.
  • Five tumors were reclassified as poorly differentiated follicular thyroid carcinomas, representing 13% of carcinomas in this unselected material.
  • High PI was also a marker of worse prognosis in malignant tumors.
  • Oxyphilic tumor cells were more frequent in carcinomas than in adenomas; however, among carcinomas, they were non-prognostic.
  • Probability for malignancy is thus greater in a male patient with a large oxyphilic follicular neoplasm.
  • The PI requires evaluation in all follicular thyroid carcinomas to identify poorly differentiated tumors with worse prognosis.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 APMIS.
  • (PMID = 20955457.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


54. Mwandila M, Waller H, Stott V, Mercer P: A case of a testosterone-secreting oncocytic adrenocortical carcinoma. N Z Med J; 2010 Nov 5;123(1325):80-2
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • Oncocytic neoplasms are most rarely found in the adrenal gland.
  • We present a case of a testosterone-secreting oncocytic adrenocortical carcinoma in a 19-year-old female who presented with acne, hirsutism and irregular menses.
  • The histology showed the tumour to be comprised of oncocytic cells with granular, eosinophilic cytoplasm, features consistent with an oncocytic carcinoma.
  • This is the first case presented of a testosterone-secreting oncocytic adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / secretion. Adrenocortical Carcinoma / secretion. Testosterone / secretion
  • [MeSH-minor] Adrenalectomy / methods. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21317966.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


55. Zagólski O, Czajecki K, Gajda M: [Diffuse hyperplastic oncocytosis of the parotid gland]. Pol Merkur Lekarski; 2006 Oct;21(124):356-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The WHO classification of salivary gland diseases considers 3 oncocytic lesions: oncocytosis, oncocytoma and oncocytic carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Parotid Gland / pathology. Salivary Gland Neoplasms / pathology. Salivary Gland Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17205777.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


56. Pezzolla A, Lattarulo S, Milella M, Barile G, Pascazio B, Ciampolillo A, Fabiano G, Palasciano N: [Incidental carcinoma in thyroid pathology: our experience and review of the literature]. Ann Ital Chir; 2010 May-Jun;81(3):165-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidental carcinoma in thyroid pathology: our experience and review of the literature].
  • [Transliterated title] Il carcinoma incidentale nella patologia tiroidea. La nostra esperienza e revisione della letteratura.
  • The diagnosis of incidental thyroid carcinoma in patients submitted to thyroidectomy for a benign disease is quite frequent.
  • A retrospective analysis was performed on 240 patients submitted to surgical intervention in order to establish the incidence of the carcinoma.
  • One hundred sixty five patients (68.75%) were affected by benign disease (132 multinodular goiter, 30 uninodular goiter, 2 Plummer and 1 Basedow) and 75 (31.25%) by carcinoma.
  • In 30 of 165 patients (18.2 %), affected by benign disease, occurred a histological diagnosis of thyroid carcinoma, (18 papillary carcinoma, 6 follicular carcinoma, 5 papillary carcinoma follicular variant and 1 oncocytic carcinoma).
  • In this study it's considered incidental thyroid carcinoma the one occurred in patients who never underwent FNA and there were no suspicious features in all exams that may suggest the presence of carcinoma.
  • Fifteen of the 30 incidental carcinoma (50%) were microcarcinomas; in the other 13, dimensions were more than 1 cm, but less than 2 cm in 9 cases.
  • Two patients had a synchronous carcinoma.
  • This study shows that the only way to put doubts on the real benignity of the disease is the fine needle aspiration; there are no other instruments that could let think about the occurrence of the carcinoma.
  • Moreover in the majority of cases the incidental carcinoma is a microcarcinoma, it doesn't reach significant volume, may be not centered by a FNAB, but in must cases it's not really biologically aggressive.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Papillary / pathology. Incidental Findings. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenoma, Oxyphilic / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Goiter, Nodular / pathology. Graves Disease / pathology. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Plummer-Vinson Syndrome / pathology. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21105480.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


57. Kunju LP, Wojno K, Wolf JS Jr, Cheng L, Shah RB: Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features. Hum Pathol; 2008 Jan;39(1):96-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary renal cell carcinoma with oncocytic cells and nonoverlapping low grade nuclei: expanding the morphologic spectrum with emphasis on clinicopathologic, immunohistochemical and molecular features.
  • Papillary renal cell carcinoma (PRCC), a morphologically and genetically distinct subtype of RCC, is morphologically separated into 2 subtypes, type 1 and 2, for prognostic purposes.
  • Type 1 PRCC (single layer of small cells, scant pale cytoplasm) is more common and has a favorable prognosis compared with type 2 (pseudostratified high-grade nuclei, abundant eosinophilic/oncocytic cytoplasm).
  • All tumors demonstrated predominant papillary architecture, lined by cells with oncocytic cytoplasm, and nonoverlapping low Fuhrman grade nuclei (1 or 2).
  • These results suggest that these tumors are distinct from type 1 (owing to oncocytic cells) and type 2 (owing to low-grade nonstratified nuclei, low stage, and good outcome).
  • Awareness of this favorable spectrum of PRCC is important to avoid its potential misinterpretation as an aggressive type 2 PRCC (owing to oncocytic cells) or rarely as an oncocytoma (owing to oncocytic cells and low-grade nuclei).
  • Morphologic spectrum of these PRCCs emphasizes that the future prognostic model of PRCC may need to be based primarily on the nuclear characteristics, irrespective of the cytoplasmic features.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Nucleus / pathology. Chromosome Aberrations. Cytoplasm / pathology. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Trisomy


58. Lappinga PJ, Kip NS, Jin L, Lloyd RV, Henry MR, Zhang J, Nassar A: HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules. Cancer Cytopathol; 2010 Oct 25;118(5):287-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMGA2 gene expression analysis performed on cytologic smears to distinguish benign from malignant thyroid nodules.
  • BACKGROUND: Up to 80% of thyroid nodules with an indeterminate diagnosis on fine-needle aspiration (FNA) (eg, "suspicious for follicular neoplasm") prove to be benign at the time of surgical resection.
  • Ancillary tests in current use are limited in their ability to improve the preoperative detection of malignant follicular thyroid nodules.
  • Studies using paraffin-embedded tissue have indicated that high mobility group AT-hook 2 (HMGA2) overexpression is present in a high percentage of malignant thyroid neoplasms but not in benign thyroid neoplasms.
  • In the current study, the ability of HMGA2 overexpression analysis to preoperatively distinguish benign from malignant thyroid nodules by reverse transcriptase-polymerase chain reaction (RT-PCR) on suspicious cytologic smears was evaluated.
  • A subset of these patients who had a cytologic diagnosis of "suspicious" underwent HMGA2 expression analysis.
  • With an HMGA2 overexpression change of 5.9-fold or greater compared with a thyroid tumor cell line as a positive cutoff, the test was found to have the following overall performance for detecting malignant nodules: sensitivity of 71%, specificity of 97%, positive predictive value of 94%, and negative predictive value of 84%.
  • HMGA2 overexpression was found to have low sensitivity for detecting Hurthle cell carcinoma (33%).
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / genetics. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Cytodiagnosis / methods. Diagnosis, Differential. Female. Goiter / diagnosis. Goiter / genetics. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20597139.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / RNA, Messenger
  •  go-up   go-down


59. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • Topoisomerase IIalpha (topoIIalpha), located at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA replication.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


60. Bouasker I, Zoghlami A, Farah Klibi F, Smaali I, El Ouaer MA, Zermani R, Dziri C: Adreno-cortical oncocytoma: a case report. Tunis Med; 2010 May;88(5):353-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adreno-cortical oncocytoma: a case report.
  • BACKGROUND: Adrenal oncocytoma is a very rare lesion, non functioning and benignin most cases.
  • AIM: This study aimed to report a new case of adrenal oncocytic tumor with uncertain malignant potential.
  • The diagnosis of adrenal oncocytoma with malignant potential was confirmed by pathology.
  • CONCLUSION: Adreno cortical oncocytoma is a rare tumor.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Adrenal Gland Neoplasms / pathology. Kidney Cortex / pathology. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517834.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


61. Chao TC, Lin JD, Chen MF: Surgical treatment of Hurthle cell tumors of the thyroid. World J Surg; 2005 Feb;29(2):164-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of Hurthle cell tumors of the thyroid.
  • Hurthle cell tumors are relatively rare thyroid tumors and their management and prognosis is controversial.
  • We retrospectively review 135 Hurthle cell adenomas and 28 Hurthle cell carcinomas of the thyroid surgically treated at our institute.
  • No significant difference was found between the adenoma and carcinoma groups in patient age, gender, and tumor size.
  • Meanwhile, most of the carcinoma patients underwent total thyroidectomy.
  • No recurrence of Hurthle cell adenomas was noted.
  • Five adenoma patients died of causes unrelated to their Hurthle cell tumors, but no carcinoma patients died during the follow-up period.
  • In conclusion, clinical factors and FNAC are not helpful in the differentiation between adenoma and carcinoma.
  • Unilateral Hurthle cell adenoma can be treated by lobectomy/isthmusectomy, and Hurthle cell carcinoma can be treated by total thyroidectomy with minimal operative morbidity.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15650796.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Yaturu S, Rainer L: Thyroid nodule with eggshell calcification and oncocytic thyroid cancer. Med Sci Monit; 2010 Mar;16(3):CS25-28
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid nodule with eggshell calcification and oncocytic thyroid cancer.
  • BACKGROUND: To report an interesting case of Hurthle cell cancer of the thyroid with eggshell calcification, including ultra-sonographic, surgical, histological, and immuno-histochemical findings and discussion of diagnostic and therapeutic strategies.
  • US-guided FNA revealed a richly cellular specimen with numerous sheets of Hurthle cells with nuclear pleomorphism and intranuclear vacuoles.
  • Microscopic examination revealed oncocytic or Hurthle cell carcinoma with pericapsular and vascular invasion.
  • We could not find any reports of Hurthle cell thyroid cancer with such coarse or eggshell calcification.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20190688.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


63. Camargo RS, Maeda MY, di Loreto C, Shirata NK, Anselmo Garcia E, Filho AL: Is agNOR and DNA ploidy analysis useful for evaluating thyroid neoplasms? Anal Quant Cytol Histol; 2005 Jun;27(3):157-61
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Eighty-one consecutive cases of thyroid carcinoma were selected for DNA and AgNOR analysis.
  • The diagnoses were: papillary carcinoma (n = 40), follicular carcinoma (n = 31), Hürthle cell adenocarcinoma (n = 4), and undifferentiated carcinoma (n = 6).
  • Counting the NORs was performed by subjectively counting the NORs in 200 malignant cells.
  • RESULTS: DNA ploidy analysis showed all Hürthle cell adenocarcinomas, 21 (67%)follicular tumors, 23 (57%) papillary tumors and 4 (67%) undifferentiated carcinomas to be aneuploid.
  • Statistical analysis showed correlation between ploidy and histologic diagnosis, but not AgNOR counting, to have prognostic value.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121637.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


64. Kuroda N, Tamura M, Taguchi T, Tominaga A, Hes O, Michal M, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Shuin T, Lee GH: Sarcomatoid acquired cystic disease-associated renal cell carcinoma. Histol Histopathol; 2008 11;23(11):1327-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid acquired cystic disease-associated renal cell carcinoma.
  • In this article, we report a rare case of hitherto undescribed acquired cystic disease (ACD)-associated renal cell carcinoma (RCC) with sarcomatoid change.
  • Microscopically, oncocytic cuboidal cells proliferated with tubular, cribriform or papillary growth patterns, and atypical columnar cells with abundant cytoplasm proliferated with papillary configuration.
  • The cytoplasm of oncocytic and sarcomatous neoplastic cells was diffusely positive for anti-mitochondrial antibody and the ultrastructural examination detected many mitochondria in the cytoplasm of oncocytic carcinoma cells and sarcomatous neoplastic cells.
  • We thus report here a case of hitherto undescribed ACD-associated RCC intermingled with oncocytic cells, translocation type RCC-like area and sarcomatoid change.
  • [MeSH-major] Carcinoma, Renal Cell / etiology. Kidney Diseases, Cystic / complications. Kidney Failure, Chronic / etiology. Kidney Neoplasms / etiology. Sarcoma / etiology
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Nephrectomy. Nucleic Acid Hybridization. Oxyphil Cells / ultrastructure. Renal Dialysis


65. Perepletchikov AM, Alroy J, Ucci A: Diagnostic utility of CD10, CD3 and electron microscopy of renal cortical neoplasms with oncocytic features. Pathol Res Pract; 2010 Jun 15;206(6):384-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of CD10, CD3 and electron microscopy of renal cortical neoplasms with oncocytic features.
  • No currently defined imaging techniques can reliably distinguish between oncocytoma and epithelial malignant lesions with oncocytic features in the kidney; therefore, patients must undergo resection or, in certain circumstances, biopsy to definitively establish diagnosis.
  • Immunohistochemical staining for CD10 and CD3, evaluation of the staining pattern and intensity, and relevant morphologic appearance are helpful diagnostic tools in discriminating between renal cell carcinoma with oncocytic features and renal oncocytoma.
  • Electron microscopy confirms different ultrastructural components of each neoplastic cell type and correlates with immunohistochemical findings.
  • [MeSH-major] Antigens, CD3 / biosynthesis. Carcinoma, Renal Cell / ultrastructure. Kidney Neoplasms / ultrastructure. Neprilysin / biosynthesis
  • [MeSH-minor] Adenoma, Oxyphilic. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier GmbH.
  • (PMID = 19942355.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


66. Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodéré F: Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery; 2007 Dec;142(6):952-8; discussion 952-8
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
  • BACKGROUND: 18-F-fluoro-2-deoxyglucose positron emission tomography ((18)FDG-PET) is useful in the detection of iodine-negative differentiated thyroid carcinoma (DTC).
  • RESULTS: Forty-five patients (31 women, 14 men), with a mean age of 55 years, with 36 papillary, 5 follicular, and 4 Hürthle carcinomas, were studied.
  • [MeSH-major] Adenocarcinoma, Follicular / radiography. Adenocarcinoma, Follicular / radionuclide imaging. Positron-Emission Tomography / methods. Thyroid Neoplasms / radiography. Thyroid Neoplasms / radionuclide imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adenoma, Oxyphilic / radiography. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Patient Selection. Prospective Studies. Radiopharmaceuticals. Thyroglobulin / blood. Thyroidectomy

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063081.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


67. Huber GF, Dziegielewski P, Matthews TW, Warshawski SJ, Kmet LM, Faris P, Khalil M, Dort JC: Intraoperative frozen-section analysis for thyroid nodules: a step toward clarity or confusion? Arch Otolaryngol Head Neck Surg; 2007 Sep;133(9):874-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case of malignant FNAC findings, the FS result did not influence treatment decisions; in case of a malignant FS result on the background of a benign, indeterminate, or nondiagnostic FNAC finding, the FS result influenced treatment decisions in 88% of cases.
  • CONCLUSIONS: Intraoperative FS did not give additional information in cases where a malignant neoplasm was predicted by the FNAC finding.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Papillary / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle. Frozen Sections. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Decision Support Techniques. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Thyroid Diseases / pathology. Thyroid Diseases / surgery. Thyroid Gland / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875853.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Russo P: Partial nephrectomy achieves local tumor control and prevents chronic kidney disease. Expert Rev Anticancer Ther; 2006 Dec;6(12):1745-51
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / surgery. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Cardiovascular Diseases / etiology. Cardiovascular Diseases / mortality. Chronic Disease. Humans. Kidney Cortex / surgery. Kidney Diseases / etiology. Kidney Diseases / prevention & control. Kidney Function Tests. Kidney Transplantation. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Tissue Donors. Treatment Outcome

  • Genetic Alliance. consumer health - Kidney Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181488.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 42
  •  go-up   go-down


69. Brunelli M, Gobbo S, Cossu-Rocca P, Cheng L, Ficarra V, Novara G, Menestrina F, Chilosi M, Martignoni G: Fluorescent cytogenetics of renal cell neoplasms. Pathologica; 2008 Dec;100(6):454-60
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent cytogenetics of renal cell neoplasms.
  • Renal cell neoplasms are a heterogeneous group of tumours in terms of pathological features and prognostic behaviour.
  • The genetics of these tumours may aid in correct diagnosis and accurate assessment of prognosis.
  • In ambiguous cases it may be necessary to utilise new markers that are capable of further discerning renal cell neoplasms.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. In Situ Hybridization, Fluorescence. Kidney Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenoma / diagnosis. Adenoma / genetics. Adenoma / pathology. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Adult. Aneuploidy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Child. Chromosome Aberrations. Chromosomes, Human / ultrastructure. Chromosomes, Human, X / ultrastructure. Humans. Kidney Failure, Chronic / complications. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19475886.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 54
  •  go-up   go-down


70. Liu L, Qian J, Singh H, Meiers I, Zhou X, Bostwick DG: Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med; 2007 Aug;131(8):1290-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis.
  • CONTEXT: The separation of chromophobe renal cell carcinoma, oncocytoma, and clear cell renal cell carcinoma using light microscopy remains problematic in some cases.
  • OBJECTIVE: To determine a practical immunohistochemical panel for the differential diagnosis of chromophobe carcinoma.
  • DESIGN: Vimentin, glutathione S-transferase alpha (GST-alpha), CD10, CD117, cytokeratin (CK) 7, and epithelial cell adhesion molecule (EpCAM) were investigated in 22 cases of chromophobe carcinoma, 17 cases of oncocytoma, and 45 cases of clear cell carcinoma.
  • RESULTS: Vimentin and GST-alpha expression were exclusively observed in clear cell carcinoma.
  • CD10 staining was more frequently detected in clear cell carcinoma (91%) than in chromophobe carcinoma (45%) and oncocytoma (29%).
  • CD117 was strongly expressed in chromophobe carcinoma (82%) and oncocytoma (100%), whereas none of the cases of clear cell carcinomas were immunoreactive.
  • Cytokeratin 7 was positive in 18 (86%) of 22 cases of chromophobe carcinoma, whereas all oncocytomas were negative for CK7.
  • EpCAM protein was expressed in all 22 cases of chromophobe carcinoma in more than 90% of cells, whereas all EpCAM-positive oncocytomas (5/17; 29%) displayed positivity in single cells or small cell clusters.
  • CONCLUSIONS: Using the combination of 3 markers (vimentin, GST-alpha, and EpCAM), we achieved 100% sensitivity and 100% specificity for the differential diagnosis of chromophobe carcinoma, oncocytoma, and clear cell carcinoma.
  • The pattern of "vimentin(-)/GST-alpha(-)" effectively excluded clear cell carcinoma, and homogeneous EpCAM expression confirmed the diagnosis of chromophobe carcinoma rather than oncocytoma.
  • CD117 and CK7 were also useful markers and could be used as second-line markers for the differential diagnosis, with high specificity (100%) and high sensitivity (90% and 86%, respectively).
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / diagnosis. Immunoenzyme Techniques / methods. Kidney Neoplasms / diagnosis. Neoplasm Proteins / analysis
  • [MeSH-minor] Diagnosis, Differential. Fluorescent Antibody Technique, Indirect. Humans. Predictive Value of Tests


71. Rago T, Di Coscio G, Basolo F, Scutari M, Elisei R, Berti P, Miccoli P, Romani R, Faviana P, Pinchera A, Vitti P: Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. Clin Endocrinol (Oxf); 2007 Jan;66(1):13-20
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients.
  • OBJECTIVE: The cytological patterns of follicular and Hupsilonrthle cell nodules are included among the indeterminate results of fine-needle aspiration cytology, because distinction between benign and malignant lesion can only be made on histological criteria.
  • The diagnostic value of atypia at cytology, clinical parameters and echographic patterns were examined to establish the risk of malignancy in 505 patients with follicular and Hupsilonrthle cell thyroid nodules at cytology.
  • RESULTS: Histological diagnosis of malignancy was carried out in 125 of 505 (25%) patients, the follicular variant of papillary carcinoma being the most frequent histotype.
  • CONCLUSIONS: Twenty-five per cent of patients with a cytological result of follicular and Hupsilonrthle cell thyroid lesion had a final diagnosis of malignancy.
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / ultrasonography. Adenoma / pathology. Adenoma / ultrasonography. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / ultrasonography. Adult. Biopsy, Fine-Needle. Calcinosis / ultrasonography. Carcinoma, Medullary / pathology. Carcinoma, Medullary / ultrasonography. Carcinoma, Papillary, Follicular / pathology. Carcinoma, Papillary, Follicular / ultrasonography. Chi-Square Distribution. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Hyperplasia. Male. Middle Aged. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201796.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Shen SS, Krishna B, Chirala R, Amato RJ, Truong LD: Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol; 2005 Jul;18(7):933-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal cell neoplasms are presumably derived from different cell types of the nephron.
  • Clear cell and papillary renal cell carcinoma (RCC) are thought to be of proximal tubular origin, whereas oncocytoma and chromophobe RCC are derived from intercalated cells of distal nephron.
  • A few molecules, such as RCC marker and CD10, have been shown to be markers for clear cell RCC and papillary RCC.
  • The expression of kidney-specific (Ksp) cadherin, a recently cloned gene thought to be transcribed exclusively in the kidney, was studied in normal human kidney, as well as in 105 primary renal neoplasms, including 42 clear cell RCC, 30 papillary RCC, 13 chromophobe RCC, and 20 oncocytomas.
  • All 13 chromophobe RCC and 19 of 20 oncocytomas showed diffuse and strong immunoreactivity for Ksp-cadherin, while only 14% clear cell RCC and 13% papillary RCC showed focal positivity.
  • The RCC marker expression was detected in 85%, 98%, 15% and 0% of clear cell RCC, papillary RCC, chromophobe RCC, and oncocytoma, respectively.
  • A few clear cell RCC and papillary RCC showed dual expression of both RCC marker and Ksp-cadherin, which appear to have distinct histologic features.
  • These results demonstrated high sensitivity and specificity of Ksp-cadherin for distal convoluted tubules, which can be used as adjunct for diagnosis of chromophobe RCC.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Biomarkers / analysis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Kidney Tubules / chemistry

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696118.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cadherins; 0 / FAT1 protein, human
  •  go-up   go-down


73. Harvey JN, Parker D, De P, Shrimali RK, Otter M: Sonographically guided core biopsy in the assessment of thyroid nodules. J Clin Ultrasound; 2005 Feb;33(2):57-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sonographically guided core biopsy and sonographically guided FNAC both had zero false-negative rates for the diagnosis of malignancy, compared with a 7.0% false-negative rate (95% confidence interval, 2.0-12.0%) for aspiration cytology when sonography was not used.
  • With core biopsy, 11% of patients required surgical confirmation of the diagnosis, compared with 43% of patients following FNAC (p <0.001).
  • [MeSH-minor] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / pathology. Carcinoma, Squamous Cell / pathology. Cytodiagnosis. False Negative Reactions. Female. Follow-Up Studies. Frozen Sections. Humans. Male. Middle Aged. Retrospective Studies. Safety. Sensitivity and Specificity. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley Periodicals, Inc.
  • (PMID = 15674833.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Matesa N, Samija I, Kusić Z: Accuracy of fine needle aspiration biopsy with and without the use of tumor markers in cytologically indeterminate thyroid lesions. Coll Antropol; 2010 Mar;34(1):53-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 351 patients with CIL [cellular follicular lesion/suspicious follicular neoplasm/suspicious Hürthle cell neoplasm (CFL/sFN/sHCN), Hürthle cell neoplasm (HCN), and follicular neoplasm (FN)] and surgical follow-up were investigated.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle / standards. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432733.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / LGALS3BP protein, human
  •  go-up   go-down


75. Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F: Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol (Oxf); 2007 Oct;67(4):547-51
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
  • [MeSH-major] Carcinoma, Papillary / blood. Neoplasm Recurrence, Local / blood. Thyroglobulin / blood. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / radiotherapy. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / blood. Adenoma, Oxyphilic / radiotherapy. Adenoma, Oxyphilic / surgery. Adult. Aged. Biomarkers / blood. Case-Control Studies. Female. Follow-Up Studies. Humans. Immunoradiometric Assay / methods. Incidence. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Radiopharmaceuticals / therapeutic use. Retrospective Studies. Sensitivity and Specificity. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561976.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


76. Baris O, Mirebeau-Prunier D, Savagner F, Rodien P, Ballester B, Loriod B, Granjeaud S, Guyetant S, Franc B, Houlgatte R, Reynier P, Malthiery Y: Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma. Oncogene; 2005 Jun 9;24(25):4155-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma.
  • The oncogenic pathways in mitochondrial-rich thyroid carcinomas are not clearly understood.
  • To investigate the possible implication of mitochondrial abundance in the genesis of thyroid tumors, we have explored the gene expression profile of six oncocytic carcinomas and six mitochondrial-rich papillary carcinomas using cDNA-microarray technology.
  • A supervised approach allowed us to identify 83 genes differentially expressed in the two types of carcinoma.
  • Of the 59 genes overexpressed in papillary carcinomas, 51% were involved in cell communication.
  • Of the 24 genes overexpressed in oncocytic carcinomas, 84% were involved in mitochondrial and cellular metabolism.
  • Our results suggest that mitochondrial respiratory chain complexes III and IV play a significant role in the regulation of reactive oxygen species production by oncocytic tumors.
  • [MeSH-major] Carcinoma / genetics. Carcinoma, Papillary / genetics. Gene Expression Profiling / methods. Oncogenes. Signal Transduction / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Actinin / genetics. Cell Communication / genetics. Cytoskeletal Proteins / genetics. Humans. Nitric Oxide Synthase / genetics. Nitric Oxide Synthase Type III. Reverse Transcriptase Polymerase Chain Reaction. alpha Catenin

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15806164.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNA1 protein, human; 0 / Cytoskeletal Proteins; 0 / alpha Catenin; 11003-00-2 / Actinin; EC 1.14.13.39 / NOS3 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


77. Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D'Armiento M: Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid; 2009 Apr;19(4):355-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.
  • BACKGROUND: Thyroid nodules that are read on cytology as follicular or Hürthle cell neoplasms (FN and HN, respectively) and indeterminate for malignancy require surgery to differentiate benign from malignant nodules.
  • METHODS: We analyzed 463 nodules with an indeterminate cytological diagnosis of FN and 140 nodules with an indeterminate cytological diagnosis of HN.
  • The histopathological diagnosis after thyroidectomy was the method for establishing the diagnosis and type of malignancy.
  • Extrathyroidal invasion in the grouped HN and FN patients who had papillary thyroid carcinoma (PTC) was more common in females than in males (62% vs. 25 %, p < 0.05).
  • The rate of Hürthle cell thyroid cancer was significantly higher in HN than in FN (5.0% vs. 0.7%, p < 0.01) and the rate of the oncocytic variant of PTC was also significantly greater in HN compared to FN nodules (23.1% vs. 1.7%, p < 0.05).
  • The rate of follicular thyroid carcinoma was almost identical in patients with HN and FN (19.2% vs. 18.8 %).
  • Hürthle cell thyroid cancer and the oncocytic variant of PTC is more common in nodules with an HN indeterminate for malignancy cytology reading than in nodules with a FN indeterminate for malignancy cytology reading.
  • Since Hürthle cell thyroid cancer and the oncocytic variant of PTC are more aggressive than other thyroid cancers, it is likely that patients with an HN indeterminate for malignancy cytology will, as a group, have more aggressive thyroid cancers than those with an FN indeterminate for malignancy cytology.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / pathology. Thyroid Neoplasms / pathology. Thyroid Nodule / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19355826.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Valladares Ayerbes M, Aparicio Gallego G, Díaz Prado S, Jiménez Fonseca P, García Campelo R, Antón Aparicio LM: Origin of renal cell carcinomas. Clin Transl Oncol; 2008 Nov;10(11):697-712
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Origin of renal cell carcinomas.
  • Cancer is a heritable disorder of somatic cells: environment and heredity are both important in the carcinogenic process.
  • The primal force is the "two hits" of Knudson's hypothesis, which has proved true for many tumours, including renal cell carcinoma.
  • In contrast, sporadic tumours would develop only if a mutation occurred in both alleles within the same cell, and, as each event would be expected to occur with low frequency, most tumours would develop late in life and in a unifocal manner [3, 4].
  • Each of the inherited syndromes predisposes to distinct types of renal carcinoma.
  • A surprising number of genetic syndromes predispose to the development of renal cell carcinoma, and genes associated with five of these syndromes have been already identified: VHL, MET, FH, BHD and HRPT2.
  • Few cancers have as many different types of genetic predisposition as renal cancer, although to date only a small proportion of renal cell cancers can be explained by genetic predisposition.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Cell Transformation, Neoplastic / genetics. Kidney / pathology. Kidney Neoplasms / genetics. Neoplastic Syndromes, Hereditary / genetics
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Chromophobe / genetics. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cell Lineage. Cell Transdifferentiation. Genes, Tumor Suppressor. Hematopoietic Stem Cells / pathology. Humans. Kidney Glomerulus / pathology. Mutation. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Oncogenes

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015066.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Number-of-references] 94
  •  go-up   go-down


79. Tickoo SK, Gopalan A: Pathologic features of renal cortical tumors. Urol Clin North Am; 2008 Nov;35(4):551-61; v
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our better understanding of the morphologic spectrum of renal cortical tumors has resulted in a clinically more relevant classification of these tumor types.
  • We now recognize that "granular cell" and "sarcomatoid" renal cell carcinoma are only nonspecific descriptors, and that such features are seen in a variety of types of renal tumors.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenoma, Chromophobe / genetics. Adenoma, Chromophobe / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Carcinoma, Medullary / genetics. Carcinoma, Medullary / pathology. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Genetic Predisposition to Disease. Humans. Kidney Diseases, Cystic / pathology. Kidney Tubules, Collecting / pathology. Neoplasm Staging / methods. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992609.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


80. Li G, Gentil-Perret A, Lambert C, Genin C, Tostain J: S100A1 and KIT gene expressions in common subtypes of renal tumours. Eur J Surg Oncol; 2005 Apr;31(3):299-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifty-five tissue samples (15 clear cell RCCs, 15 papillary RCCs, 7 chromophobe RCCs, 8 oncocytomas and 10 normal renal tissues) were studied The gene expressions of S100A1 and KIT were analysed by one-step RT-PCR by using the specific primers.
  • RESULTS: S100A1 was expressed in 2/15 clear cell RCCs, 11/15 papillary RCCs, 7/8 oncocytomas and in 0/7 chromophobe RCCs.
  • KIT gene was expressed in 6/7 chromophobe RCCs and 7/8 oncocytomas while 0/15 clear cell RCCs and 1/15 papillary RCCs expressed kit gene.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / chemistry. Adenoma, Oxyphilic / chemistry. Carcinoma, Papillary / chemistry. Carcinoma, Renal Cell / chemistry. Cell Line, Tumor. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15780567.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 146909-89-9 / S100A11 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


81. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M: Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol; 2005 Apr;18(4):535-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemistry for aquaporin-1, aquaporin-2, PAX-2, CD10, and cytokeratin 7 was performed on 102 clear cell renal cell carcinomas, 44 papillary renal cell carcinomas (among them 34 type 1 and 10 type 2), 24 chromophobe renal cell carcinomas, three collecting duct carcinomas (carcinomas of the collecting ducts of Bellini), and 29 oncocytomas.
  • Aquaporin-1 expression was found in clear cell renal cell carcinomas and papillary renal cell carcinomas of both types (78 and 73%, respectively), but not in chromophobe renal cell carcinomas, collecting duct carcinomas, and oncocytomas.
  • PAX-2 and CD10 was found in the majority of clear cell renal cell carcinomas (88 and 85%, respectively) but only in few papillary renal cell carcinomas, chromophobe renal cell carcinomas and oncocytomas.
  • Decrease or loss of aquaporin-1 and PAX-2 was shown in higher grades compared to lower grades of clear cell renal cell carcinomas (P<0.0001 and <0.0245, respectively).
  • Cytokeratin 7 was rarely seen in clear cell renal cell carcinomas, type 2 papillary renal cell carcinomas, and oncocytomas, but was found in the majority of type 1 papillary renal cell carcinomas (97.1%) and chromophobe renal cell carcinomas (88%).
  • Aquaporin-1 and PAX-2 expression was found to correlate with nuclear grading for clear cell renal cell carcinomas but not for papillary renal cell carcinomas.
  • Aquaporin-1 and PAX-2 are reliable markers for clear cell renal cell carcinomas of lower grades but not for higher grades.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Aquaporin 1. Aquaporin 2. Aquaporins / biosynthesis. Blood Group Antigens. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA-Binding Proteins / biosynthesis. Humans. Immunohistochemistry. Keratin-7. Keratins / biosynthesis. Kidney / chemistry. Kidney / pathology. Neoplasm Staging. Neprilysin / biosynthesis. PAX2 Transcription Factor. Tissue Array Analysis / methods. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502805.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP1 protein, human; 0 / AQP2 protein, human; 0 / Aquaporin 2; 0 / Aquaporins; 0 / Biomarkers, Tumor; 0 / Blood Group Antigens; 0 / DNA-Binding Proteins; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Transcription Factors; 146410-94-8 / Aquaporin 1; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


82. Sav A, Scheithauer BW, Mazzola CA, Ketterling SR, Thompson SJ, Reilly MH: Oncocytic choroid plexus carcinoma: case report. Clin Neuropathol; 2010 Jan-Feb;29(1):14-20
Genetic Alliance. consumer health - Choroid Plexus Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic choroid plexus carcinoma: case report.
  • Herein, we report an unusual choroid plexus carcinoma with extensive oncocytic transformation.
  • Microsections revealed a WHO Grade III choroid plexus carcinoma with extensive oncocyti c transformation.
  • A minor portion of the moderately to poorly differentiated tumor exhibited classical microscopic features of choroid plexus carcinoma, including marked nuclear atypia, brisk mitotic activity (78/10 HPF), a high MIB-1 labeling index (44%) and zones of necrosis.
  • In contrast, the large, eosinophilic, cytologically malignant but granular-appearing oncocytes comprising the majority of the lesion showed scant (1/10 HPF) mitotic activity and only a low MIB-1 labeling index (5%).
  • A subsequent recurrence at 1 year consisted entirely of non-oncocytic tumor.
  • Choroid plexus carcinoma with oncocytic transformation has not been previously reported.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain / pathology. Carcinoma / pathology. Choroid Plexus Neoplasms / pathology
  • [MeSH-minor] Family. Female. Humans. Infant. Magnetic Resonance Imaging. Oxyphil Cells / metabolism. Oxyphil Cells / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040328.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, Teixeira MR, Jerónimo C: Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer; 2007;7:133
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
  • In this study we aimed at defining a quantitative gene promoter methylation panel that might identify the most prevalent types of renal cell tumors.
  • METHODS: A panel of 18 gene promoters was assessed by quantitative methylation-specific PCR (QMSP) in 85 primarily resected renal tumors representing the four major histologic subtypes (52 clear cell (ccRCC), 13 papillary (pRCC), 10 chromophobe (chRCC), and 10 oncocytomas) and 62 paired normal tissue samples.
  • CDH1 hypermethylation levels were significantly higher in ccRCC compared to chRCC and oncocytoma (p = 0.00016 and p = 0.0034, respectively), whereas PTGS2 methylation levels were significantly higher in ccRCC compared to pRCC (p = 0.004).
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenoma, Oxyphilic / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Papillary / genetics. Carcinoma, Renal Cell / genetics. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics. Neoplasm Proteins / metabolism
  • [MeSH-minor] Cadherins / isolation & purification. Cadherins / metabolism. Cyclooxygenase 2 / isolation & purification. Cyclooxygenase 2 / metabolism. DNA Methylation. Diagnosis, Differential. Humans. Membrane Proteins / isolation & purification. Membrane Proteins / metabolism. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / isolation & purification. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2990-7 [8065911.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4097-106 [15930345.001]
  • [Cites] World J Urol. 2005 Jul;23(3):202-12 [15812574.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Urol. 2006 Jun;175(6):2302-6 [16697863.001]
  • [Cites] Urology. 2006 May;67(5):873-80 [16698345.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5021-8 [16707423.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1747-52 [11717336.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):605-12 [11839581.001]
  • [Cites] Urology. 2002 Dec;60(6):941-6 [12475646.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1370-5 [12684406.001]
  • [Cites] Methods Mol Biol. 2003;226:33-4 [12958476.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 5;95(21):1634-7 [14600096.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7641-5 [14633683.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8695-9 [14695183.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):381-93 [15122209.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3972-9 [15217927.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4010-4 [15217932.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5511-7 [15289362.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):805-10 [15375503.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7276-83 [15534102.001]
  • (PMID = 17645803.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDH1 protein, human; 0 / Cadherins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  • [Other-IDs] NLM/ PMC1940017
  •  go-up   go-down


84. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M: Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res; 2005 Sep 15;11(18):6558-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
  • PURPOSE: Morphologic distinction among clear cell, papillary, and chromophobe types of renal cell carcinoma (RCC) can be difficult, as is the differential diagnosis between oncocytoma and RCC.
  • RESULTS: CA9 expression was highest in clear cell carcinoma and lowest in chromophobe RCC and in oncocytoma.
  • AMACR expression was highest in papillary RCC, and CLCNKB was highest in chromophobe RCC/oncocytoma.
  • PVALB was highest in chromophobe RCC, variable in oncocytoma, and low in clear cell and papillary types.
  • This algorithm accurately classified the 31 fresh-frozen tumors into 14 clear cell, 5 papillary, 6 chromophobe, and 6 oncocytomas.
  • In the formalin-fixed group, the molecular criteria accurately classified the cases into 15 clear cell, 16 papillary, and 32 in the chromophobe/oncocytoma group but could only separate some, but not all, oncocytomas from chromophobe RCC.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Adenoma, Oxyphilic / genetics. Adenoma, Oxyphilic / pathology. Algorithms. Anion Transport Proteins / genetics. Antigens, Neoplasm / genetics. Carbonic Anhydrases / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Chloride Channels / genetics. Diagnosis, Differential. Humans. Membrane Proteins / genetics. Racemases and Epimerases / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. beta-Defensins / genetics

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166433.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anion Transport Proteins; 0 / Antigens, Neoplasm; 0 / CLCNKB protein, human; 0 / Chloride Channels; 0 / DEFB1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / beta-Defensins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


85. Brocks BA, Peeters ME, Kimpfler S: Oncocytoma in the mandibular salivary gland of a cat. J Feline Med Surg; 2008 Apr;10(2):188-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytoma in the mandibular salivary gland of a cat.
  • Initial investigations suggested a malignant salivary gland tumour, and the mass was removed by extracapsular resection of the mandibular gland.
  • Histopathology showed an oncocytoma within the salivary gland.
  • An oncocytoma is a neoplastic transformation of oncocytes.
  • Physiological proliferation occurs next to oncocytosis, oncocytoma, and oncocytic carcinoma.
  • This is the first report of an oncocytoma in a feline mandibular salivary gland, and the first report of long-term survival after surgical removal.
  • [MeSH-major] Adenoma, Oxyphilic / veterinary. Cat Diseases / diagnosis. Salivary Gland Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160323.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Pino Rivero V, González Palomino A, Trinidad Ruíz G, Keituqwa Yáñez T, Marcos García M, Pardo Romero G, Pantoja Hernández CG, Blasco Huelva A: [Hürthle cells carcinoma. Report of two operated cases and review of the literature]. An Otorrinolaringol Ibero Am; 2005;32(5):467-73
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hürthle cells carcinoma. Report of two operated cases and review of the literature].
  • [Transliterated title] Carcinoma de células de hürthle. Descripción de dos casos intervenidos y revisión de la literatura.
  • Hürthle cells carcinomas are considered a variant of folicular carcinomas and represent about 2% of all malignant thyroid tumours.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318090.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


87. Foschini MP, Gaiba A, Cocchi R, Pennesi MG, Pession A: p63 expression in salivary gland tumors: role of DeltaNp73L in neoplastic transformation. Int J Surg Pathol; 2005 Oct;13(4):329-35
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors: p63 antibody was positive in the following: Warthin tumor (WT) (3/3), oncocytoma (OC) (1/1), pleomorphic adenoma (PA) (7/7), polymorphous-low-grade adenocarcinoma (PLGA) (3/3), adenoid-cystic carcinoma (ADCC)(3/4), epithelial-myoepithelial-cell carcinoma (EMC) (1/1), and myoepithelial-cell carcinoma (MCC) (1/1).
  • By RT and nested PCR all tumors expressed p63 irrespective of their morphologic differentiation.
  • [MeSH-major] Cell Transformation, Neoplastic. Phosphoproteins / genetics. Phosphoproteins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Trans-Activators / genetics. Trans-Activators / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenolymphoma / metabolism. Adenolymphoma / pathology. Adenoma, Oxyphilic / metabolism. Adenoma, Oxyphilic / pathology. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Adult. Aged. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Cell Proliferation. DNA-Binding Proteins. Exons. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Male. Middle Aged. Myoepithelioma / metabolism. Myoepithelioma / pathology. Polymerase Chain Reaction. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction. Salivary Glands / cytology. Salivary Glands / metabolism. Salivary Glands / pathology. Transcription Factors. Tumor Suppressor Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273188.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / Protein Isoforms; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


88. Kobayashi K, Nakao K, Yoshida M, Ando M, Ebihara Y, Asakage T, Yamasoba T: Recurrent cancer of the parotid gland: how well does salvage surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec; 2009;71(5):239-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the definitive surgery group, the presence of lymph node metastasis and high-grade malignant histopathology were associated with a poor prognosis (p < 0.01).
  • [MeSH-major] Carcinoma, Adenoid Cystic / mortality. Carcinoma, Adenoid Cystic / surgery. Neoplasm Recurrence, Local / mortality. Parotid Neoplasms / mortality. Parotid Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adenoma, Oxyphilic / mortality. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Mucoepidermoid / mortality. Carcinoma, Mucoepidermoid / secondary. Carcinoma, Mucoepidermoid / surgery. Facial Paralysis / mortality. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / secondary. Neoplasms, Glandular and Epithelial / surgery. Prognosis. Retrospective Studies. Salvage Therapy / mortality. Skull Base / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19738397.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


89. Chahwala Q, Siddaraju N, Singh N, Goneppanavar M, Basu D: Fine needle aspiration cytology of oncocytic lipoadenoma of the parotid gland: report of a rare case. Acta Cytol; 2009 Jul-Aug;53(4):437-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of oncocytic lipoadenoma of the parotid gland: report of a rare case.
  • BACKGROUND: Oncocytic lipoadenoma is an uncommon benign salivary gland tumor.
  • Fine needle aspiration cytologic (FNAC) findings of oncocytic lipoadenoma have not yet been documented.
  • FNAC showed moderate cellularity, with oncocytic cells arranged predominantly as microacini in a prominent lipoid background.
  • The adipose tissue background of the cytologic smears was ignored as material derived from the normal fat tissue; based on the oncocytic population of cells, a diagnosis of oncocytoma was considered.
  • A remote possibility of acinic cell carcinoma with oncocytic features was also suggested.
  • However, histopathologic examination showed it to be an oncocytic lipoadenoma, a tumor we were unaware of at the time of cytodiagnosis.
  • CONCLUSION: Both cytopathologists and histopathologists need to be aware of oncocytic lipoadenoma of the salivary gland in order to diagnose it precisely.
  • The clinicocytopathologic correlation highlighted in our case will be useful for cytopathologists in preoperative interpretation and diagnosis.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697732.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Manxhuka-Kerliu S, Devolli-Disha E, Gerxhaliu A, Ahmetaj H, Baruti A, Loxha S, Thaqi H: Prognostic values of thyroid tumours. Bosn J Basic Med Sci; 2009 May;9(2):111-9
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Follicular adenomas have been found in 39, 1% of cases, thyroid carcinomas in 60, 12%, whereas thyroid secondary carcinomas have been found in 0, 72% of cases.
  • As far as histological variants of thyroid carcinomas are concerned, most frequently found were papillary carcinomas in 39,85% of cases; followed by follicular carcinomas in 9,42% of cases; follicular variants of papillary carcinomas in 5,79% of cases; medullary carcinomas in 3,62% of cases, while anaplastic and Hurthle cell carcinomas have been found in 0,72% of cases each.
  • Papillary carcinoma has been found in 80% of female cases.
  • Our data indicate that apart from the fact that papillary carcinomas, well differentiated, and characterised by relatively good prognosis, were most frequent variants, certain morphological variants of it were associated with poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19485942.001).
  • [ISSN] 1512-8601
  • [Journal-full-title] Bosnian journal of basic medical sciences
  • [ISO-abbreviation] Bosn J Basic Med Sci
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


91. Demasi AP, Furuse C, Altemani A, Junqueira JL, Oliveira PR, Araújo VC: Peroxiredoxin I is overexpressed in oncocytic lesions of salivary glands. J Oral Pathol Med; 2009 Jul;38(6):514-7
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroxiredoxin I is overexpressed in oncocytic lesions of salivary glands.
  • BACKGROUND: Oncocytic lesions, particularly frequent in the salivary glands, are characterized by cells with an atypical accumulation of mitochondria.
  • Peroxiredoxin I (Prx I) is a H(2)O(2) scavenging protein and the expression of its yeast homolog was reported to be influenced by mitochondrial function.
  • METHODS: In this study, we evaluated Prx I expression in oncocytic lesions of salivary glands by immunohistochemistry.
  • [MeSH-major] Oxyphil Cells / enzymology. Peroxiredoxins / analysis. Salivary Glands / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenolymphoma / enzymology. Adenolymphoma / pathology. Adenoma, Oxyphilic / enzymology. Adenoma, Oxyphilic / pathology. Antioxidants / analysis. Biomarkers / analysis. Carcinoma, Mucoepidermoid / enzymology. Carcinoma, Mucoepidermoid / pathology. Free Radical Scavengers / analysis. Gene Expression Regulation, Enzymologic. Granular Cell Tumor / enzymology. Granular Cell Tumor / pathology. Humans. Hydrogen Peroxide / analysis. Hyperplasia. Lysosomes / pathology. Metaplasia. Mitochondria / pathology. Reactive Oxygen Species / analysis. Salivary Gland Neoplasms / enzymology. Salivary Gland Neoplasms / pathology. Thyroid Gland / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19298244.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Free Radical Scavengers; 0 / Reactive Oxygen Species; BBX060AN9V / Hydrogen Peroxide; EC 1.11.1.15 / Peroxiredoxins
  •  go-up   go-down


92. Milas M, Barbosa GF, Mitchell J, Berber E, Siperstein A, Gupta M: Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol; 2009 Feb;16(2):473-80
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These cells express thyrotropin receptor (TSHR) messenger RNA (mRNA), which has been studied as a marker of initial TC diagnosis.
  • Thirty-four patients underwent 20 +/- 14 months median follow-up for papillary (n = 31, 91%), follicular (n = 2) or Hurthle cell (n = 1) TC.
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / secondary. Adenocarcinoma, Follicular / surgery. Adenoma, Oxyphilic / blood. Adenoma, Oxyphilic / secondary. Adenoma, Oxyphilic / surgery. Adult. Aged. Autoantibodies / blood. Biomarkers, Tumor / blood. Carcinoma, Papillary / blood. Carcinoma, Papillary / secondary. Carcinoma, Papillary / surgery. Cell Differentiation. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Thyroglobulin / blood. Thyroglobulin / genetics. Thyroglobulin / immunology. Thyroidectomy. Thyrotropin / pharmacology. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19015922.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


93. Albores-Saavedra J, Hernandez M, Sanchez-Sosa S, Simpson K, Angeles A, Henson DE: Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions. Am J Surg Pathol; 2007 May;31(5):729-36
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic variants of papillary and follicular carcinomas associated with anaplastic spindle and giant cell carcinomas of the thyroid: an analysis of rhabdoid and thyroglobulin inclusions.
  • We describe the histologic variants of papillary and follicular carcinomas associated with 109 spindle and giant cell carcinomas (SGCC) of the thyroid and determine the incidence of rhabdoid and thyroglobulin inclusions in these tumors.
  • In addition, we searched for rhabdoid and thyroglobulin inclusions in 120 papillary carcinomas (PC) (all 15 variants included), 23 differentiated follicular carcinomas (DFC), (6 with insular pattern), 6 poorly differentiated follicular carcinomas (PDFC) and 34 follicular adenomas (FA).
  • The following differentiated thyroid carcinomas coexisted with SGCC: 51 (46.8%) PC, (34 conventional type, 14 tall cell variant and 3 follicular variant), 6 (5.5%) DFC, 1 follicular carcinoma with insular pattern (0.9%), and 3 oncocytic carcinomas (2.8%).
  • Thyroglobulin inclusions were found in 10 FA (29%), 8 (17%) follicular variants of PC and in 7 (30.4%) DFC.
  • The finding that only 1 (0.9%) SGCC was associated with follicular carcinoma with insular pattern contradicts the opinion that this tumor occupies an intermediate position between differentiated and anaplastic carcinomas.
  • Rhabdoid features are markers of PDFC and SGCC while thyroglobulin inclusions are markers of FA and differentiated thyroid carcinomas with follicular phenotype.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Giant Cell / pathology. Carcinoma, Papillary, Follicular / pathology. Inclusion Bodies / pathology. Rhabdoid Tumor / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460457.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9010-34-8 / Thyroglobulin
  •  go-up   go-down


94. Carling T, Ocal IT, Udelsman R: Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg; 2007 May;31(5):916-23
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Recently, more aggressive variants of so-called well-differentiated thyroid carcinomas have been identified such as the tall cell variant, columnar cell variant, diffuse sclerosing variant, insular carcinoma, and Hürthle cell (oncocytic, oxyphilic) carcinomas.
  • The clinical presentation, pathophysiology, diagnosis, and surgical and medical management for these thyroid cancers with intermediate differentiation are discussed.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Adenocarcinoma, Follicular / surgery. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17345120.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


95. Little JW: Thyroid disorders. Part III: neoplastic thyroid disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep;102(3):275-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most of these tumors are benign hyperplastic or colloid nodules or benign follicular adenomas.
  • However, 5% to 10% of the lesions that come to medical attention are carcinomas.
  • A major clinical challenge is establishing which nodules are hyperplastic, benign, or malignant.
  • History, clinical findings, ultrasonography, and fine-needle aspiration biopsy are the mainstays for diagnosis.
  • Differentiated lesions are subdivided into papillary, follicular, and Hurthle cell carcinomas.
  • An important neoplastic syndrome, multiple endocrine neoplasia type 2 (MEN2), involves medullary carcinoma of the thyroid gland.
  • The overall 10-year survival for papillary carcinoma is 80% to 90%, follicular carcinoma 65% to 75%, and medullary carcinoma 60% to 70%.
  • The prognosis for anaplastic carcinoma is very poor and 5-year survival is rare.
  • The dentist by inspection and palpation of the neck in the area of the thyroid gland may detect single or multiple lesions that may be benign or malignant.
  • Patients with identified nodules or enlarged thyroid glands should be referred for diagnosis and treatment.
  • [MeSH-major] Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / blood. Adenoma / diagnosis. Carcinoma / blood. Carcinoma / diagnosis. Carcinoma, Medullary / blood. Carcinoma, Medullary / diagnosis. Diagnosis, Differential. Humans

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920533.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Melck A, Bugis S, Baliski C, Irvine R, Anderson DW, Wilkins G, Zhang H, Wiseman SM: Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg; 2006 May;191(5):593-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm.
  • BACKGROUND: The objective of this study was to evaluate the cancer risk of patient clinicopathologic characteristics to determine the optimal approach for the surgical management of individuals with Hurthle cell neoplasm (HN) diagnosed by cytology.
  • The association of these characteristics with a pathologic cancer diagnosis was evaluated using Fisher's exact test and Student t test.
  • RESULTS: Of the 422 patients undergoing thyroidectomy, 27 presented with a fine-needle aspiration biopsy diagnosis of HN, and by pathologic assessment 7 HN patients (25.9%) had a cancer diagnosis.
  • Although none of the clinicopathologic characteristics evaluated were able to reliably differentiate benign from malignant tumors, large tumor size and male sex were significantly associated with a pathologic diagnosis of Hurthle cell carcinoma (P < .05).
  • CONCLUSIONS: Hemithyroidectomy represents the preferred initial surgical approach for the management of individuals presenting with nodular thyroid disease and a cytologic diagnosis of HN.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647343.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Elliott DD, Pitman MB, Bloom L, Faquin WC: Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis. Cancer; 2006 Apr 25;108(2):102-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
  • BACKGROUND: Lesions of the thyroid gland composed of Hurthle cells encompass pathologic entities ranging from hyperplastic nodules with Hurthle cell metaplasia to Hurthle cell carcinomas.
  • Many cytologic features of Hurthle cell lesions that distinguish neoplastic Hurthle cell lesions requiring surgery from those that are benign and nonneoplastic have been described, but with variable usefulness.
  • A morphologic study was made of 139 Hurthle cell lesions of the thyroid gland and statistical analysis applied to identify a set of cytomorphologic features that distinguish benign Hurthle cell lesions (BHCL) from Hurthle cell neoplasms (HCN).
  • METHODS: Fine-needle aspiration biopsies (FNABs) of thyroid nodules with a predominant Hurthle cell component and corresponding histologic followup were included in the study.
  • Cases were divided into BHCL and HCN groups on the basis of the histologic diagnosis.
  • All cases were reviewed to assess the following 14 cytologic features: overall cellularity, cytoarchitecture, percentage of Hurthle cells, percentage of single cells, percentage of follicular cells observed as naked Hurthle cell nuclei, background colloid, chronic inflammation, cystic change, transgressing blood vessels (TBV), intracytoplasmic lumina, presence of multinucleated Hurthle cells, nuclear to cytoplasmic ratio, nuclear pleomorphism/atypia, and nucleolar prominence.
  • Six of the 14 cytologic features evaluated were shown by univariate analysis to be statistically significant in predicting HCN: nonmacrofollicular architecture (P < 0.001), absence of background colloid (P < 0.001), absence of chronic inflammation (P < 0.001), presence of TBV (P < 0.001), > 90% Hurthle cells (P < 0.001), and >10% single Hurthle cells (P = 0.014).
  • CONCLUSIONS: In the current study of 139 FNAB specimens of thyroid Hurthle cell nodules, 14 cytologic features were examined and 6 were found to be statistically significant in identifying HCN.
  • [MeSH-major] Adenoma / pathology. Adenoma, Oxyphilic / pathology. Oxyphil Cells / pathology. Thyroid Gland / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Cell Nucleus / pathology. Colloids / analysis. Cytoplasm / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Logistic Models. Male. Metaplasia / pathology. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16453320.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Colloids
  •  go-up   go-down


98. Deandrea M, Ragazzoni F, Motta M, Torchio B, Mormile A, Garino F, Magliona G, Gamarra E, Ramunni MJ, Garberoglio R, Limone PP: Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation. Thyroid; 2010 Oct;20(10):1077-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation.
  • To date, however, among lesions showing a follicular pattern, FNAC is still unable to differentiate between benign and malignant ones.
  • The aim of our study was to evaluate whether a subclassification of follicular cytologic specimens, based on cytoarchitectural patterns, could differentiate categories with a different risk of malignancy, thus improving the clinical management of patients harboring follicular nodules.
  • All the cytologic specimens were divided into five categories (Thy 1: inadequate material, Thy 2: benign, Thy 3: indeterminate, Thy 4: suspicious for malignancy, Thy 5: malignant).
  • Thy3 specimens were further divided into three subcategories (Thy 3a, or "follicular lesions of indeterminate significance": scant colloid, microfollicular pattern, or small clusters of thyrocytes with round nuclei usually without, but sometimes with, minimal cellular pleomorphism; Thy 3b, or "follicular neoplasm": absence of colloid, small clusters, or microfollicles of medium-large sized cell populations arranged in cohesive groups with nuclear overlapping, crowding, and pleomorphisms; and Thy 3c or "Hurthle-cell neoplasm": scant colloid, sheets or clusters of oxyphilic cells).
  • RESULTS: Thy 1 specimens (51 cases on the whole) proved to be malignant in 5.88% (3 cases), Thy 2 specimens (319) in 3.45% (11 cases), Thy 4 specimens (91) in 84.62% (77 cases), and Thy 5 specimens (172) in 98.84% (170 cases).
  • Thy 3 specimens (294 cases) proved to be malignant in 17.35% as a whole, but when divided into the three subcategories, the percentage of malignant cases was significantly different between the Thy 3a group (4.95%) and the Thy 3b and Thy 3c groups (25.0% and 22.77% respectively).
  • CONCLUSIONS: This study supports the National Cancer Institute consensus showing a different risk of malignancy for "follicular lesions of undetermined significance” compared with "follicular neoplasms" and "Hurthle cells neoplasms," which are more suspect for malignancy.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Thyroid Gland / pathology. Thyroid Nodule / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Humans. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20883171.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Rubio V, Tamarit JM, Baviera N, Fernández S, Estrems P, Seijas T, López C, Dalmau J: [Methodology for evaluation of malignancy screening in surgical thyroid gland disease]. Acta Otorrinolaringol Esp; 2009 Nov-Dec;60(6):390-5
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evaluación metodológica para detección de malignidad en patología quirúrgica tiroidea.
  • The specific sensitivities towards papillary carcinoma of FNA and extemporaneous biopsy were 81% and 88%, whilst for follicular carcinoma they were 66% and 62.5%, respectively.
  • CONCLUSIONS: FNA has good sensitivity in clinical suspicion of thyroid papillary carcinoma, although it should be complemented by extemporaneous biopsy due to its better specificity.
  • In the case of follicular carcinoma there is a tendency towards conservative treatment, without carrying out extemporaneous biopsy previously and with reintervention in case of definitive malignancy.
  • [MeSH-major] Adenocarcinoma, Follicular / diagnosis. Adenoma / diagnosis. Carcinoma, Papillary / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / radionuclide imaging. Adenoma, Oxyphilic / surgery. Adenoma, Oxyphilic / ultrasonography. Adolescent. Adult. Aged. Aged, 80 and over. Biopsy / methods. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Palpation. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Thyroid Diseases / diagnosis. Thyroid Diseases / pathology. Thyroid Diseases / radionuclide imaging. Thyroid Diseases / ultrasonography. Thyroidectomy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19850274.001).
  • [ISSN] 1988-3013
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


100. Kim HJ, Shen SS, Ayala AG, Ro JY, Truong LD, Alvarez K, Bridge JA, Gatalica Z, Hagenkord JM, Gonzalez-Berjon JM, Monzon FA: Virtual-karyotyping with SNP microarrays in morphologically challenging renal cell neoplasms: a practical and useful diagnostic modality. Am J Surg Pathol; 2009 Sep;33(9):1276-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virtual-karyotyping with SNP microarrays in morphologically challenging renal cell neoplasms: a practical and useful diagnostic modality.
  • Approximately 7 % of renal cell tumors are reported to be "unclassified" renal cell carcinoma (RCC) under the current (morphology-based) classification.
  • Tumors were classified by the established pattern of genomic imbalances based on a reference cohort of 98 cases with classic morphology and compared with the morphologic diagnosis of the pathologist panel.
  • All cases with a panel diagnosis of unclassified RCC and cases in which a majority diagnosis was not reached were classified by their virtual karyotypes.
  • In 1 case, the molecular-based diagnosis was in disagreement with the majority diagnosis.
  • One case with a majority diagnosis of oncocytoma showed a novel genomic pattern not previously identified in the classic morphology cohort.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma, Oxyphilic / genetics. Kidney Neoplasms / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. DNA, Neoplasm / analysis. Gene Expression Profiling. Humans. Image Processing, Computer-Assisted. Karyotyping / methods. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461508.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down






Advertisement